var title_f32_33_33296="Radial head and neck fracture";
var content_f32_33_33296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Radial head and neck fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 312px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE4Ac0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6D+F88tz8NPCU9zK808ukWjySSMWZ2MKEkk8kk966auV+E/8AySzwb/2BbL/0QldVQAUUUUAFFFFABRVa91CzsLW4ur67t7a2t/8AXTTSKiR9PvMTgdR19RVXRvEGja5byz6Lq+n6jBCcSSWlykyoevJUkD8aANOisvRfEWi660y6JrGnai0BxKLO5SYxn/a2k4/Gl0jX9G1mW4j0fVtPv5LdtsyWtykpiPowUnB4PWgDTooooAKKKKACuZ8JTyy6/wCNUlld0h1eNI1ZiQi/YLRsL6DLMcDuSe9dNXK+Df8AkY/Hf/Yaj/8ATdZ0AdVRRRQAUUUUAFFFFABRRRQAUVHLPDCHMssaBELuWYDao6k+g96zNG8T6BrdzLb6Lrml6jPEN0kVpdxzMgzjJCkkUAa9FZVv4j0O51mXSLbWdNm1aLPmWUd0jTpjrmMHcMfSnQeINGuNYl0m31fTpdViBMlklyjTJjrlAdw/KgDTooooAKKy7zxFotlqsGmXmsadb6lcECG0lukSaQngbUJyc+wpL/xHoenanBp2oazptrqE+PKtZ7pElkycDahOTk+goA1aKzNR1/RtMv7ax1LVtPtL26/1FvcXKRyS84+VSQW544rToAKKKKACiiigAooooAK5n4oTy23w08Wz20rwzxaRdvHJGxVkYQuQQRyCD3rpq5X4sf8AJLPGX/YFvf8A0Q9AHVUUUUAFFFFABRRRQAUU13VBl2VQSFyTjknAH5nFZuueItF0BYm13WNO0xZSRGby6SEOR1xuIzQBqUVl614i0XQmhXW9Y07TmnOIheXKQmQ/7O4jP4Uur6/o+ixQS6xq2n6fHcNthe6uUiEh9FLEZP0oA06KRWDKGUgqRkEcgiloAKKKKACvmX9tHWtV0f8A4Q7+yNTvrDzftnmfZbh4t+PIxnaRnGT+Zr6ar5V/bn/5kn/t+/8AbegD6A+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqACiiigArzv4m/wDCWfbrX+zvtn/CLbP9O/sXb/ae/P8ABv48vGM7P3nXFeiUUAcP4R/4QU+EGTRf7POivdBZ1u87musoQJvO+czZEf3/AJvu+1eVfEUahBcfFOC4niv9cbw7BI91p0Rgjht97AwvFuch9u9yxdsqeigYr6Cv9NsdRtJ7XULK2urWf/WwzxK6ScAfMpGDwB19Kg0fQdH0S2kt9G0qw0+3kOXitLZIkb6hQAaAPOtXtdOvvir4TtNEKLaz+Hb2K5NocYsm8kQYI6DcW2/pW74J8CXHh7UbC6vtVgvRpum/2VZpb2ItsQ7lbMpDtvf5F5AVR8xC5JrptF8O6LoTTNomj6dpzTnMps7ZITIf9raBn8a1KACiiigAooooAK5Xwb/yMfjv/sNR/wDpus66quV8G/8AIx+O/wDsNR/+m6zoA6qiiigAooooAKKKKACuP+Jf/CW/2Xbf8Id5ePM/03y9n2vyuP8Aj38z93v6/f49Oa7CigDznwAfBa6frJtjKL4Q51o69u+2bNp/4+PN/gxu6fu8ZxxWZqivB8ZPCRkmsbyGWwvV0mKwi8k2cexTvl+ZvNQgBVI2KD/Cc5Hqs1vDMsizRRyLIhjcOoIZT1U+o9qzNE8M6DoMssuh6JpemySjEj2dpHCXHoSoGaAPDtE8j/hU/wAK/s2z+2/+Egts4/1vnec/2rf/ABfd8zf+vavRdI+HMthrVlM2rxS6VYanc6rbW4sttx50+/cJLjed6jzW42gn5QSQK6638OaHbazLq9to2mw6tLnzL2O1RZ3z1zIBuOfrWrQBQ1qXVIbRW0Szsry53gGO7u2tkC4OTuWOQ5zjjb688cz6c93JZRNqUEEF2R+8igmMyKfZyqE/ioqxRQB4F8ONX1fw74au/EN0dMu5r3XpbbUbCO2Y6jLM1y0SqJTIFLKCpEZQfIOozRrH2H/hC/jl/bGz7f8AbpseZ/rNv2aL7J17b/u/jivaV8O6KutHWF0fThq5GDfC2Tz+mP8AWY3dOOtJf+HND1HU4NR1DRtNutQgx5V1Pao8seDkbXIyMH0NAHCX/wAO77Xre4nn1ZLX+29MtbPV4prITSnyxyYZC48tvmPVXweQAea9PAwABnA9TmlooAKKKKACiiigAooooAK5X4sf8ks8Zf8AYFvf/RD11Vcr8WP+SWeMv+wLe/8Aoh6AOqooooAKKKKACq2p/bP7Ouv7L+z/AG/ym+z/AGjPleZj5d+3nbnGcc4qzRQB434c+z/8JLY/8LV/tD/hKftC/Yftn/IL87I2/ZNn7vdnbjzP3ucY5qhFeavpvjz4l+I/tOix3GlNEPK1GB3lezWFXVIpBIohViW52uC55HGD7i6K4w6qwBDYIzyDkH8xms3UPD2i6lqFvf6jpGnXd9b48m5ntkkkiwcjaxGV554oA810S8sNQ+Ivja98RW720Fz4dsJo4L9QskVoyzGdSMkABiAwBI3Cqnw+8H6rrHw/8GavHqcVlqa6EdOkF9Y/a0a2kwVwpdSrbQvOSCOCpFeq614d0XXWhbW9H07UWgOYjeWyTGM/7O4HH4VpqoVQqgBQMADgAUAUPDulRaFoGm6TbPJJBY20dsjyHLMqKFBJ9eK0KKKACiiigAr5V/bn/wCZJ/7fv/bevqqvlX9uf/mSf+37/wBt6APW/hl400u1+G3hO3ltfEDSRaTaRsYtAv5EJEKA7XWEqw9CCQeoJrpf+E80j/nz8Sf+E5qP/wAYo+E//JLPBv8A2BbL/wBEJXVUAcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXVUUAcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXVUUAcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXVUUAcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXVUUAcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXVUUAcr/AMJ5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/Cc1H/4xXVUUAcr/AMJ5pH/Pn4k/8JzUf/jFc14T8aaXDr3jN3tfEBWfVo5FCaBfsQPsFovzAQkqcqeGwcYOMEE+n1yvg3/kY/Hf/Yaj/wDTdZ0AH/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xXNfE3xppd18NvFlvFa+IFkl0m7jUy6BfxoCYXA3O0IVR6kkAdSRXp9cr8WP+SWeMv+wLe/8Aoh6AD/hPNI/58/En/hOaj/8AGKP+E80j/nz8Sf8AhOaj/wDGK6qigDlf+E80j/nz8Sf+E5qP/wAYo/4TzSP+fPxJ/wCE5qP/AMYrqqKAOV/4TzSP+fPxJ/4Tmo//ABij/hPNI/58/En/AITmo/8AxiuqooA5X/hPNI/58/En/hOaj/8AGKP+E80j/nz8Sf8AhOaj/wDGK6qigDlf+E80j/nz8Sf+E5qP/wAYo/4TzSP+fPxJ/wCE5qP/AMYrqqKAOV/4TzSP+fPxJ/4Tmo//ABij/hPNI/58/En/AITmo/8AxiuqooA5X/hPNI/58/En/hOaj/8AGKP+E80j/nz8Sf8AhOaj/wDGK6qigDlf+E80j/nz8Sf+E5qP/wAYr5q/bK1601v/AIRD7HDqUXk/bN323Tbi0znyMbfORd3Q525xxnGRX1/Xyr+3P/zJP/b9/wC29AH0B8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXVUAGBRgUUUAGBRgUUUAGBRgUUUAJgUh606mnrSEFFFFABTqbTqECBulcn4N/wCRi8d/9hmP/wBN1nXWN0rk/Bv/ACMXjv8A7DMf/pus6AOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisfxT4l0nwrpbajr14lpaKwXc2SST2AHJP0oAi8Z+KNM8IaFPqusziOCMfKo+9I3ZVHcmuD+CXjfxN45udY1HVNPittBMmLJ8YYeqg/xe59a67xT4W8N/EXRbL+1IlvbIFbi3mikKnn0YdiOCK6PT7K206xgs7GCOC1hQJHFGMKoHYCgZYooooEFFFFABXK/Fj/klnjL/sDXn/oh66oVyvxYx/wqzxlx/wAwa8/9EPQB1VFLkelGR6UAJRS5HpRkelACUUuR6UZHpQAlFLkelGR6UAJRS5HpRkelACUUuR6UZHpQAlFLkelGR6UAKvSvlX9uf/mSf+37/wBt6+qh0r5V/bn/AOZJ/wC37/23pjPoD4T/APJLPBv/AGBbL/0QldUTiuV+E/8AySzwb/2BbL/0QldU3SgBM0ZpKKQhc0ZpKKAFzRmkooAXNJRRQAUUUUAFOptOoQIG6Vyfg3/kYvHf/YZj/wDTdZ11jdK5Pwb/AMjF47/7DMf/AKbrOgDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACivLfi78XNO8EQfYdPEWo+IHIVLRXyIs9DJjkew6mvIte0Pxprnh+fxP8TfE1zoeiZDx2MYbzGJ+6qxAgAntuJNA7H1cc9q8E8Q/DTxT4++J0svjSeOPwtZHdbJbP8ALKp/hA6hv7xP4V4z4M1bxl4StP8AhLdGbUG8NxXIikFxIWjmB/vJnBOONw6GvtHw7qkGt6FY6naEmC7iWVcjpkdKYbFnT7O30+ygs7KJIbaBAkcaDAVR0AqxRRSEFFFFABRRRQAVyvxY/wCSWeMv+wNef+iHrqq5X4sf8ks8Zf8AYGvP/RD0AdVRRRQAUUUUAFFFcp8SfGdh4G8Mz6rfjzHHywQBgGlfsBnt6mgDq6Q8da+YfD3gvxl8Y5Br/i3WbnStIfP2SCAFTjsUTgY/2jyar63ofir4F6xb61pmpz6v4clkEdwkzHHPZ1yRn0YUx2PqYUtUtG1CHVdJtL+2OYbmJZV5zwRmrtIQUUUUAFFFFADl6V8q/tz/APMk/wDb9/7b19VL0r5V/bn/AOZJ/wC37/23pjPoD4T/APJLPBv/AGBbL/0QldU3SuV+E/8AySzwb/2BbL/0QldU3SgBtFFFIQUUUlAC0Vna3rmlaFatcazqNrYwj+O4lCZ+mev4V5Z4n/aF8HaQxi003esz5wPs0eyM/wDA2xn8AaAPZKqX+pWOnRCTULy2tYycbp5VjGfqSK+epfHHxZ+IAEfhHQToenv0unG0lf8ArpIAP++Vq/o/7OsV7It5438R3+pXrYMiQt8v03vlj+GKAPaF8U+H3YKmu6UzE4AF5GST+dbCsGGQcg9/WvFbz9m/wRJbSLatqdvOR8kv2gPtPrtIwaw/g1e6t4I+J1/8PtW1Br2wEe+zaRsBeMjaCTjI/hzQM+h6dTadQAN0rk/Bv/IxeO/+wzH/AOm6zrrG6Vyfg3/kYvHf/YZj/wDTdZ0COqooooAKKKKACiiigAooooAKKKKACiikzQAteWfGX4r2Xgmxax0xorzxFP8AJFbqQ3kk/wATgfovU1l/F34vpo80vhvwfHJqHiaU+VmFPMWAnsMfef27d6T4L/CUaHnxD4tUXviS6/eYm+cW+eep6v6nt2pjsc94A8OWfgvSrz4g/FR0k1a6bzIlnXzJEz0wvdz6dhXsumXmgfEDwmtxFHHf6PfIQ0cyEZ9QQehFed+OvhRq/jb4jQXuvauknhWBQY7SPKyKe6Y6c92zn2rQ+JnxM0P4a6PHpGiQ28+rRoI7fTo/uwjsXx0Ht1NAzG/aR1XSvD/w4i8LWEKRz3uyK1toRgIinr/T3r0v4a2FxpXgLQbG8UJcQ2iK6g9DjOP1ryP4V/DbWtf8TDxz8RizXbMJbS0Y9P7pYfwgdl/Ouv8Ajb8ToPA+mrY2C/aNfvEIt4gDiMHjecfoO5oEepcUtfH9onjj4VyaN4t1a6u5LTU5d1/ayzEjk8BwSfmI56cdK+tdKvoNS021vbRt9vcRrIh9QRmkKxbooooAKKKKACuV+LH/ACSzxl/2Brz/ANEPXVVyvxY/5JZ4y/7A15/6IegDqqKKKACiiigAr5n8SpL8WvjmuiiUP4f0U5lUM21sfe7YyTx/WvXfjR4vXwb4Evr1HAvJl8i2GeS7Dr+A5rlf2ZPCkui+EJdZv9327WG847hyE7c+/WmM9gt4Ut4I4YkCRxqFVR0UAYAryP8Aah1e3svhs9iyJLc6hMsUKkAkY5LD0NevSyJFE8kjBY0UszHoAOpr5ot3l+M3xmE4bd4X0JsqGGA+D+pYjv2FID3P4YadNpPw+0CxucedDaIGAGME8/1rp6agCoAoAAGAB0ArzX4m/GHQvA0gs9jalq562du4zH6F27fTk+1Aj0ykJr57/wCGiL+zlC614E1C1Dx748SNlvQ4aNfl9xmq7fE/4q+J5Gfwp4PFlaxx+bm4gZy647M+wN7BRQFj6Nor530/9om40pI7Txn4Vv7XUEISRo/kB9TscAj6An61698PvHGmeO9Mn1DRob2O3ik8om6iEe4/7OCcigDrF6V8q/tz/wDMk/8Ab9/7b19VL0r5V/bn/wCZJ/7fv/bemM+gPhP/AMks8G/9gWy/9EJXUt0rlvhP/wAks8G/9gWy/wDRCV1LdKAG1x/ir4leEvCzNHrGtWyXC9beI+bKPqq5I/GvKviX4y8TeNvGM/gb4euI4oRi9vEcowI+8N4PCj25NdB4I+APhnRkiuNfD63qON0hmJEG71Cd/wDgRNAGNqv7RUd7ctZ+CvDGoarcE7Y3lUgE/wC4gZv5fhVAL8cfGxDbovDNjKMEDEBA+nzSfyr6C0zTLDSrcQaXY2tlCP8AlnbxLGv5ACrfvQB4Jo37OVjLOt14v8Rajq9wR8yxkxjPf5mLMR+VeoeGfh34U8MoBo+iWUUg6zSR+ZKf+Btk11n0rmfFPjrwz4WVv7c1m0tpQP8AU798p+iLk/pQI6akrwHWP2jbW4ujZ+DvDt/q1yeEaT5dx/3FDMR+VUxF8c/GfzNLb+GrKTOFOIWUY9Buk/kfpSA9w8UeJ9H8L6dJe67fwWkKDOHb529lXqx+leD/AAtk/wCFi/HDU/GMVo0elWSbIWkBBLYwvfG7GSRWzof7PUE+pjUfHPiC91y4PLICyhvZnYliPpivbNI0yw0bT4rHS7WG0s4RhIol2qopjLwp1UtN1Ky1OF5dOu4LqJHMbPC4dQw6jI7irtAA3SuT8G/8jF47/wCwzH/6brOusbpXJ+Df+Ri8d/8AYZj/APTdZ0hHVUUUUAFFFFABRRRQAUUUUAFFFQXl1BZ28txdSpDBEpd5HbaqgdSTQBK7KilmYKoGSSeAK8D+KPxZv9T1mPwh8NGW81Kc+XNeQ/OF7EIenHdu1ZHjPx7r3xT12fwf8OgE0ojFzqBJXevclh91PoMmu/8AD3h/wr8FPBcmoX7xNeBP314VHmzv/wA807geg/E0x7Gd4F8B6X8JPD1/4l8QM+o6ukZknuI42coD1VByeT1Y1ifCrVvG3xD8et4qe6m0zwvBmJLUcpOv9wA9T3LfgK9W+HvjGx8f+GF1O0s54IpC0UkNwnfuAejD6V5n8TvikmnOfBfw1szc60f3AaziBjt/VYwvVh+QoA1vi78W00Gd/DnhaNtR8UT4jVYl3LAx9fV/b86pfBz4RHTZT4k8coL7xFcN5ojnxILc/wB49i/v27VpfBT4VReEYf7Y10i68S3I3PIx3+QD1UE9W9Wq38ZPina+BbRLLT1S98Q3A/c23URg/wATgc/QdTQBd+L3xLsPAGkcFLjWZ1ItrUHr/tN6KP1rhvgv8PtV1TWz488eEzahcfvLW3mXJQHo5B+7x0Han/C/4U3+qa0vjT4jy/atUnImhsZBkRH+Ev8ATsvQV70BgYoC9jiPjRoSa/8ADfWbTyhJMkJmi+UsQy85AHfrWJ+zdrR1b4XWETkmWyZrZhg9jxknqa9MvoVuLOeGQEpJGyEDqQRivCP2WphaT+LdFbzke2vN6wvnCLkjv3oA9+ooopCCiiigArlfix/ySzxl/wBga8/9EPXVVyvxY/5JZ4y/7A15/wCiHoA6qiiigAprcDnp706vM/j345Hg3wZKtsc6nqGbe3AOCuR8z/gKAPM/EN0fi98arTR7bzG8P6IxaZh0cqfmP4ngV9KxosUaRxqFRQFUDsB2rzH9n3wWPC3giG5u4gNV1L/SJ3I+YA/dUn6c/jXpl1PHbW0s87BIo1Lux6AAZJoGzyL9o/xqdA8MrounF21fV/3SBOqR5wT+PQV03wZ8Gw+CvBFpaGNVvp1E92+OWcjofoOK8j8AWUvxV+MN/wCLL4FtE0qXbbow4Yj7gH8zXvHjrxNZ+D/C95rOoZMUAwqL1dz91R9TTAZ4s8a+HvCduZNd1W1tZCu5IXf94/0Uc+2cV4l+zjodn4m8QeI/F2qWK3MpvCbSa4+cxknJIB/ixjmoPhJ8P4viNc6h408fR3F0lxMfssEkjKjJ6nuVHQYOK968JT+HTYtZ+FJtNa0tG8porF1KxN6EL0P1oA3eaKKKQjzH9oy+isPhZqbyLG0spWGIvFvwzHt6fWr3wJ0ddF+F+iw7Csk0X2iTcm07m55/xrhf2r7tpNJ8PaRGJ2a8vQSiHhwMDB9TzXtmiWy2ejWNsilFigRApPIwo4NMZoL0r5V/bn/5kn/t+/8AbevqodK+Vf25/wDmSf8At+/9t6APoD4T/wDJLPBv/YFsv/RCV1D/AHTg4PrXL/Cf/klng3/sC2X/AKISupbpQB86/AadNN+L3jbS9RdhqE0jNGJFCs4DZPA9iK+ia8d+K3wku9f16PxN4O1JdJ8QRAZ6ospHRty8hvwOa5u78HfG7WokstT8VWNrakfNJby7G6dykasfzoA9i8V+OPDfhRc6/q9raSEblhLbpGHsgyx/KvH9U/aDudYvW074feGbrUrskhJJwTn3EaZOPqRWx4S/Z78PafILrxNcXGvXzcuJWKRbu5wDub/gRr13R9H03RLUW2kWFrZW4/ggiCD8cdaAPn6XwX8YPHik+Jtdi0OyfrapJt+U/wCxF1+jNXU+Fv2efCmmMs2tS3et3PVvPby4if8AdXk/iTXsjsiqWdlVR1JOAK43xF8UvBegK/27xBZPKo/1Ns/nSH8EzQB0uk6Npmj2y2+k6fa2UK9EgiVB+lXicduK+ftR/aIl1SZrPwJ4XvtSuicK8wz+OxMn8yKqHwj8XPiIyf8ACV6svh/Sn5NvD8rY9PLQ5P8AwNvwoA9K8efF/wAKeD43jnvlv9QA4tLNhI2f9ps7V/E/hXzt8Q/ih4z8ZwW8CW82kaLeyeXbxQBgbg5xy/Bcc9sCvevAvwP8JeFWE8tsdXvhz518oZVP+yn3R9Tk1w3jSJPF37R2h6IEV7HSYldo12ALj5iP5cdaAR7X4A0JPDnhDSdLRdpt4FD8YyxGSTwO5ro6aKdQAN0rk/Bv/IxeO/8AsMx/+m6zrrG6Vyfg3/kYvHf/AGGY/wD03WdIR1VFFFABRRRQAUUUUAFFFFABXzz8b9c1bxj43s/h14YufKR8G+dc49cMRzgDkivoU9K+atJ1MeFP2jvEk+tmWWS5gdrYCMKZuMqijPJOMD1oGj2/wB4Q03wXoEGmabCm5VHnXGwB527sxHX+lcj8SvhS/jrxjpd/f6vIuiWy4lsADkn/AGT0Ge5PPpXn3g608V/Fzx9F4n1Oe70fQdMmP2aOJijZB+4vqf7zH6VtfGT4oXl1qQ8E/D/fdaxct5NxcwHPl56op9fVu1Mdiv8AFT4hvBJB8PfhjAGvWAtXktRxCOnloR39W7V3Hwc+F9n4D077Rc7LrXrhf9IueuzP8Ce3qe9Q/Cf4c6Z8N9Dl1HVZoX1eRN95eysAsQ6lVJ6D1PeuC8dfFHWfHusHwj8MIpGSYNHcXxUqSO5Vv4E/2up7UCOl+LfxdOl3cvhjwZDJqPiWb91uhXesDHsAPvP7dB3pnwe+DqaRJD4k8YF73xHKTMI5X3rAT3P95/ftXQ/CT4U6X4Fs0uZgt5r8i/vrxskLnqqA9B79TXpYGBQFwpaKKQhK+ffgwbjTfjj450yeNMykylg2cfNkfzr6Dr588FXP2T9qHxPbywyBrqNthxgAAA5+lA0fQdFFFAgooooAK5X4sf8AJLPGX/YGvP8A0Q9dVXK/Fj/klnjL/sDXn/oh6AOqooooAjmlSGNpJWCooLMx6ADqa+atBS5+L/xql1Sbc/hrQ3xEDjacH5R+J5rrv2mfF1zpeg2vhvSlLX+snyzgHIjzjA9yeK7T4QeDYvBHg2007713IPOuXxgmQjp9B0pjsdtjArxn9pTxbLpnhqDw7pbE6nrLeSFT7wjzg/meK9iup47W3lnuHCQxKXdj0AAyTXzn8OIZPid8Y9S8XXqltI0pvLtFb7pI4XH/AKFQCPV/h9odh8OPh1bw3ssVutvF9ovJ3IA3kZbJ/SvCvib4z074m694OtI7qa00aa5eO5hLgFW34DH6jp9a3Pi54lv/AIkeMbfwF4Pd3skk/wBOuYjuRsdd3+yv15NeR/EjwPe+BvG8elWrS3BkKSWc2ArSkkY6d93FA7H2zJolqPDMmi2aCC0+zG2jVONo247V8SeG/DXi0+Mr/wAP+E572K/ikaKaSzuWjRUB+87qQMV9vaJHdSeHbKPUg0d41sqzBTyrbcHn1r5S13wrf+GPjHF4c8B+JdQt73UFzNOzcxliWwxT7w+oyKAR9V+F7K50vw9p9jfXTXl3BCqSzsSTIwHJyeT+Natcf8M9E8SaFostt4u1xdavDKWjnAOVT0JIBNdfSJZ89/HUrqnxk8C6SbohFdXdFwSh3ZBx7gV9Cc5r591cHV/2qrCOK33iwtg0m/bjhc7h+f1r6DoGxy9K+Vf25/8AmSf+37/23r6qXpXyr+3P/wAyT/2/f+29MD6A+E//ACSzwb/2BbL/ANEJXVN0rlfhP/ySzwb/ANgWy/8ARCV1TdKAG15X4w+OXhbwvqlxpt3Bqs1/BkPGlrtAPYEuR19RkV6nXlXxq+FNt43sTf6aI7bxDAv7qXoJgP4H/oe1IEcfL+0BrOrFovCfgW/updud0pd9pJ4O1F5H/AhSi/8Ajv4kc/Z7Kx0CBn+86xoU4/2i7Efhmtv4EfEttWjPhXxRN5PiOxJhUSAL56rxgHuwxz617TkHvTA+eIvgZ4q8RuJPHfje5nBwWggLyjr0yxCj2O2uy8PfATwLo4Vp9Pm1OUY+e9mLAn12rhfwxiuZ/ai8W6to0Gj6XpU13p8VzJ5st9ESvQ8KCOfcise/+POqS3Wl6J4GtYdXujCscl3qCmNp5cfwqWXH49aAPojTdMsdMhEOm2lvaQ8fJBEqDj2Aq33ryf4W3XxVu9cEvjq2s7fR2iYiNVjWRX/hyFJOK9ZpCGuwVGY5wBk4r56+Accuu/FTxp4kl3tGJWgRnjA5LdOOhwK9q8dX/wDZng3WrwAExWshALbeduOv415n+yppv2f4eTagyp5l/dO5YEkkDgZzTGe006m06kIG6Vyfg3/kYvHf/YZj/wDTdZ11jdK5Pwb/AMjF47/7DMf/AKbrOgDqqKKKACiiigAooooAKKKrXl9aWXlfbLqC381xHH5rhd7Hooz1PtQBmeMvE+meEtCn1XWJxHbxjCrn5pG7Ko7k14uNJt/j94cbV2sZ9A1eymMdte7d8cyZyB1BOO5HQ9M16V8Sfhrpfj+fS31W4uolsZN5SI/LKp6qc9PqOa7DTbG102wgsrCCO3tYFCRxRjAUDtQM+dW8FfG14DoMmvwDSSnlm6FwgBX6hPNz/nNdd4c8PeD/AIG6HLqetags+rTrh5mAMsh/uRJ1xnr+pr2VhkEZx7188fFT4Ha9ruo3Gtaf4jk1W93FltdQAXanUIjD5QPbAFMLmMZvF/x81PyUEmi+C4n+YgBg5Hvxvb2+6K9/8D+D9G8F6Oun6HaiFTgyyHl5W/vMf6dBXkvww+Lx0+/j8J+PdNi0G+gHlRzeX5MRxwAynhc9mHBr3pGDoGUgqwyCDkEUAxs8sdvDJNMwSONSzsewAyTXDfED4k6T4Y8FHXrO5t77zxtskjkysznpyOw71P418deGNLS/0bUdbsrbUntpNsEj4PKnAJ6DPua+XPgz8MJ/iBfy3E9zHBo1nLtn5JkcnnaoHTPrn86AR6/8Fv8AhYfinVLbxbrniOP+xZNwGnowIde3yKMLj3+b1r3kdK8r+HPwctPAnimXVdO1u+ntXRkFnKoCjPckHkj1xXqtIGFeCW3/ACdjP/2D/wD2Sve68Etv+Tsp/wDsH/8AslAI97ooooEFFFFABXK/Fj/klnjL/sDXn/oh66quV+LH/JLPGX/YGvP/AEQ9AHVUh6UtFAHzssA8V/tRzfaULW2ixfKrbfvKOCB3GT9a+ia+cPivZan8OPinB8QtOsRdaTcDZdhRypIw2fTPGD0r0C0+OfgObSlvJNZ8mQpuNq8L+aD/AHcAYJ/GmOxmftM+KJNI8GJpFhKRqOrOIVRRlin8WPTPArjvEmsN8LvhhpHg/QoyfFOrRBpPKJ8yMv1bp1OcD0qt4QGofF34q3Piv7HjR9JQixjus+WZB9xWIHrycVFrPwi+Jx8Sz+KYdQ0afWml8xPLmJKem3zU2gAdKAR6p8EPh0ngnw99ovgJNdvR5l1KwBZM8+Xn27+9Z/7R3hL+3vBn9qWQK6ppLefE6nBK/wAS/wBa51D+0AqBSujNgYyfJyf1rxv4uT+Or3xRbab42YvqJRVhtrZh5TAnghVJBOfxoGfQnhb4i6prXwjg1Xw9pZ1jxFAFtpLQH+Mcb25Bxjms34OeCvE0njXUfHHjaKK0v7tCkdqANy57kDoMdOc+tdb8FfAUHgrwtCJraKPWLpA95JG7Hcew+Y8Y9gK9DAAoEFFLRSEfP3gZZ9S/ad8UXcjxgWULRbQvLLwBX0DXz58BI5b74s+PNSuZ2eZJTFggfMN3X9K+g6AHL0r5V/bn/wCZJ/7fv/bevqpelfKv7c//ADJP/b9/7b0xn0B8J/8Aklng3/sC2X/ohK6pulcr8J/+SWeDf+wLZf8AohK6pulADaQjIxS0UhHivx1+F661C/ifwyHtvElkBKfIGDcBfp0cdj3rgtS+NuteI/CWn+HdDtrm18WXUgtZ5k46cZU9VY9/TmvqbivnrwZZ2x/aj8SEQRjyoWdMKBtYgZP1plXOLvvhf431Lx3pOg+Jb7VtU00gSyXryyPFECPnCsxYBh09/Suz+HvwHOieO7q41+G31HRoAHsJfNKtvzkF0HcflX0MKWlcVxB0paKKBHlv7SV81l8J9UCFMzskJDdwTzj34rd+DGnf2X8MtAt8RBjbiRjGMAluc/WvO/2sJZJdE8PabEkbG7vgNzHGCMY/DmvbNEtvsWkWVttRPKgRCqdAQoBxQPoXadTadQhIG6Vyfg3/AJGLx3/2GY//AE3WddY3SuT8G/8AIxeO/wDsMx/+m6zoA6qiiigAooooAKKKzfEOtWHh7SLjU9XuEt7OBdzu3f0AHcnsKANByQjEAsQM4HU186P4X8RfF34jTXviW0vdG8NaTN5UVvISruVP8PuepYfhXe/CPx9rXj3UNWu5dHW08OI+2yuGYiRyOoI/i9cjGOnNen0Acf8AFDTvP+G+r29tNJbyW9t5kEqu26Nk5BBBznjrmvAvh5+0Nq+nrBY+KbJ9WhwFWe34ufxHR/0P1r6j1aJp9Lu4Y13PJC6KvqSpAr5V8TfC7WfhvoOk+MNLmZ9WspvOvo0IZIwW428dMcHr1pjR9P8AhjW4fEGlRX9ta31tHJ0jvLdoX/Ju3uK1jXP+AvEtv4u8LWGs2oCi4T50BzscfeX866CkI4f4ofDnSfHujyQ3cUcOpKv+j3qoN8Z7AnqV9RXjfhn4ga/8Ko7vwp4/t7owpC/9nXkQEh6EKFOeVz68jvX05XGfFnwpY+LPBuoW97bJLPBE01tITtaNwM5DdqBpnzx8DvAmnfEf/hJb/wASCW7uVb91K1w6sJGBOWAIz26mvZPgD4K1vwRo2q2OuxWqiW58yBoWDFlxjLEfyPSuc/ZGskh8I6vc/N50t3scZ4+UY4r3mgGFFFFAgrwS2/5Oyn/7B/8A7JXvdeCW3/J2M/8A2D//AGSgEe90UUUAFFFFABXK/Fj/AJJZ4y/7A15/6Ieuqrlfix/ySzxl/wBga8/9EPQB1VFFFAEVzBHcwvDPGksTjayOoZWHoQa4K7+DXgK5u1uJPDlqrAlisbOiNn1UHBr0KigLlLSNMstHsI7HS7SC0tIxhIoUCqPwFXaKKACvn3xZLFN+1N4dRGR2jtwHAIO04PX0r6Cr59s4re6/axujIscvk2e5ec7HCfzoQ0fQI6UtFFAgqK6YrbSspwwQkH8Klqhr8rwaFqMsRxIltIynGcEKcUAeIfstWzzXfjHVJpmeeW9MTAgc8k5r36vDf2Trd/8AhDtXvpJN7Xd8xZduMEDn8817lQA5elfKv7c//Mk/9v3/ALb19VL0r5V/bn/5kn/t+/8AbemM+gPhP/ySzwb/ANgWy/8ARCV1TdK5X4T/APJLPBv/AGBbL/0QldU3SgBtFFFIQV89fCC3lvfj543v5rhma23R7WGcgtgc9sV9CHgE18/fs8Szah8SfHuomAxxSS7Cc5AbeeM/QZoGj6CooooEFFFFAHzv8e/J1P4veB9LMUkrK4eRApwQXzxjntX0OBgYHSvn/XUn1P8Aaq0qFpEVLG2EqfL1XaSR9a+gaBsKdTadQhIG6Vyfg3/kYvHf/YZj/wDTdZ11jdK5Pwb/AMjF47/7DMf/AKbrOgDqqKKKACiiigClq2qWOj2L3mq3cFpaIQGlmcKoJOBya5/x/wCCtH+IOiQ2eqNKYVcTQz28mCPp2IIryvx74L8ZfEj4lHTNcH2DwhYkSRvC2UlU+nrIff7te7aRptvpOmWthYoY7a3jEUakk4AHrTGQ6Bo1hoGk22m6TbJb2duu1EUdPc+p960adijAoAbVTVLC31PT7myu4w9vcRtG6kdQRiruBSHikI+b/gjcS+APihrfgfU5GW3uW32ZY/KxHII+q/yr6Pr58/ab0t9K1Pw740skbzrKdY5mGSMA5U9CB3Fe7aJfx6ppFnfwHMdxEsq/iM0DLtUdd/5Amo/9e0n/AKCavVk+LLtLLwzqtzMGMcdrISFGT900CPJ/2T/+RI1P/r/evbq8P/ZMYP4F1Fh0N85/OvcKAYUUUUAFfPWkXqXn7WV9tVl8m1eE7u5VByPbmvoWvAvACK37THjJmUFljOCR06dKENHvtFFFAgooooAK5X4sf8ks8Zf9ga8/9EPXVVyvxY/5JZ4y/wCwNef+iHoA6qiiigAooooAKKKKACvnz4cR213+0n4xuV2yNCreW6tkAnAPTrX0GSAMk4Ar55/Z5itp/id49u0CO6zFUkVsjaXOcY4oGfQtLRRQIK534h3j6f4G126iVXeOzkIVuhyMf1roq434xXUNn8M/EMlwxVDasgIGeTwKAON/ZWt5YfhiJZV2rPdSSIcg5FeyV5Z+zR/ySPSvUPJ/OvU6AHL0r5V/bn/5kn/t+/8AbevqpelfKv7c/wDzJP8A2/f+29MZ9AfCf/klng3/ALAtl/6ISuqbpXK/Cf8A5JZ4N/7Atl/6ISuqbpQA2iiikIZIypG7uwVFUkk8ACvBf2X5Fl1Pxu8bBka/yrA5BGTzXuGs/wDIHvv+uEn/AKCa8X/ZMiQeFdclCKJG1BgWA5IHQZoA91ooooAKKKQnAyelAHz14JS3v/2ofEtwZPONvE3lsr5AOACP/rV9DV8+/AU29z8XfH9zH5cv7z93IADwX5wa+gqACnU2nUIEDdK5Pwb/AMjF47/7DMf/AKbrOusbpXJ+Df8AkYvHf/YZj/8ATdZ0AdVRRWb4h1qw8PaTcanq9yltZQLueRv5D1J9KADxDrWn+HtIudS1e5S2s4F3O7Hr7D1J9K8l+FfxD8U+PvHN/c2thHD4OjUxqZRhlYdCG/iY9x0Ar0Ip4b+Jvg5S6pqOjXg3DOVZSPyKsPzra0HRtP0DSoNN0i2S1s4F2pGnb3J7n3NMZorwK8r+LnjqCznuvC9lr1nod8bM3VzfXFykLxRkHakAYjdK5UgEZ2DnrtB9VqC/tUvrG5tJSwjniaJivUBhg49+aAPGNNn1fxT8PPhtfaVcatrdvDGv9trperiC4kP2Ygq8nnRksJCpIL59a01kk17whCPBS+JPLtNa8vWdPudTlXUNqLiSBJ5ZTsOTE2FkUEZwwLEnsIvBi2mh6Fpeka9rWmR6Rbi2hltpIi0qBVX96skbIxwoOdowc4xmtHwl4bsvDGnS2li9xM8873Vzc3Mm+W4mfG6RzgDJwBwAAAABQBS+Hdpq9l4d8rXjciU3ErW8V1cC4nhgLHy0klBO9wOpy3YbjjNdM1LSNQB5R8dta8O3XhPV/DWoanb22rSW/n28M67d5XkbWbCk/Q5rivg38WLa38I+HfDFvaTah4gaX7MsCAIkcefvs3TgZ969X+KvgWy8d+GZrGdY476MFrW5K5MT/wCB6EV4r+zB4QubHxtr11qtvJFc6WPsmGU4Eh68/SgOh9PVznxHP/FB69/15yfyro64f42yPF8K/EbxO6P9mI3KcHqKQjnP2XVA+EliQACZ5ckDrzXrdeafs6WS2Xwm0cI5bzt8xyOhJ6fpXpdABRRRQAlfPnwluX1P9oPxrexwOkQVo2PUKQccn3xX0JXgXwB/5Kj8Q/8Arv8A+zUDR77RRRQIKKKKACuV+LH/ACSzxl/2Brz/ANEPXVVyvxY/5JZ4y/7A15/6IegDqqKKKACiiigAooooAgvpEhsbiSRgsaRszE9gAcmvCv2U0iktvFl5HGp8y/wku3G5eTgH0r2Hxpepp/hHWbqVWZI7SQkL1Pykf1rzL9lKORfhvLI8bKkt5IyEjAYe1AHtFFFFABXnf7QP/JJNf/65D/0IV6JXk37T8jx/Ca92Oyhp4lbacZGeh9qAOh+CSqvwq8N7VAzagnAxk5NdxXK/CyzXT/h34ftkdnVLRDuYYPIz/WuqoAcvSvlX9uf/AJkn/t+/9t6+ql6V8q/tz/8AMk/9v3/tvTGfQHwn/wCSWeDf+wLZf+iErqm6Vyvwn/5JZ4N/7Atl/wCiErqm6UANooopCMPxvNJB4P1qWFykiWkhVh1B2mvMv2UbIwfDeW7aXebu7dyMfdI469813/xSvF0/4eeILl0Lqlo4IU4PIx/WuR/Ziglh+E1j5qMgeaV0z/EpPBoA9YooooAKjmYJE7MQFCkknoOKkqjrn/IFv/8Ar3k/9BNAHiH7LojfUPGsyhGY3+A4AyVyT19K99rwv9kyGJfCOsTLGole/ZWcDkgdAa90oAKdTadQgQN0rk/Bv/IxeO/+wzH/AOm6zrrG6Vyfg3/kYvHf/YZj/wDTdZ0AdVXzV+0BBNe/EPSrHxl4hh07wk0ZniWGORm4OGBVQcufXoBX0rWH4g8JeH/EUsUuvaPZahJECsbXMQcqD1AzQBz3wy8V+CdQto9C8EXSPHZRBvJWCSPavTJLKMkmtfxj468OeDWth4j1EWZuM+V+5kfdjr91TVjQPB/h3w9cyXGhaLYafPIux3t4QhZfQkVL4g8LaF4jMJ17SbLUDDny/tMQfZnrjNAGR4T+JXhTxZqTaf4f1X7XdqhkKeRInyjvllAq94x8a6B4NitpfEd/9jS4YrEfKeTcRyfug4p2heC/DXh+9N3omh6fYXRXYZbeEIxX0yKseIfDOieI0hTXtKs9QWEkxi5iD7CeuM0AYvhb4n+EfFWqjTdC1b7VelC4j+zyp8o68soFani/xhofg6zhuvEd79jgmfy428p5MtjOMKCai0TwR4X0K/F7o2g6dY3aqVE0EARgD1GRV7xB4d0fxFbxwa7ptrqEMTb0S4jDhT6gGmM5/wAN/FTwb4k1eLTNF1gXN9KCUj+zypkDryygfrWz4u8V6N4S09L7xDefZLZ3Eav5bvlvTCgmq+j+BfCui36X2k+H9Ns7xAQs0MCqy564IrR17QdJ8QWq22uafbX9urbxHcRh1DeuDSA5jQfix4L1/VrfTNI1kXF9cHbHH9mlXcfqVAFbHiPWdA8GWdxrOsSR2MM7qk06xMxdui5Cgk/WotL8A+EtJv4r7TPDul2l5EcxzQ26qyn2Na+uaLpmvWX2PWbG3vrTcH8mdA65HQ4NAjktG+LvgjWtUttO0zWhPe3L7Io/s0y7m9MlAB+NZf7SdxLbfCXVTDIyF2jRsH7yk8iuo074e+ENNvobzT/DelW13C2+OWK3VWQ+oPavP/2rppE+HMESSsizXkaOoP3hQM7T4M2X9n/DLw9Bv8z/AEYNuxjrzXa1ieCrNdP8I6PaxuzpHaRgFup+UGtugQUUUUARznEMn+6f5V4L+y3axG88ZXe0/aDfGItk/dyTjH1r3HWpHh0e+ljbbIkEjKfQhTivFv2T7dz4Z1zUJJS8l1fHcNuMEdT+OaYz3aiiikIKKKKACuV+LH/JLPGX/YGvP/RD11Vcr8WP+SWeMv8AsDXn/oh6AOqooooAKKKKACiiigDh/jXePYfC7xBPGqu32YphunJxWX+zlZy2Xwl0dZtv73fKu05+UnjPvVP9py7Nr8J75Um8tppo49u7BcZ5HvXWfCizSw+HPh+3iZnRbRCC3Xnnt9aYHWUUUUgCvGv2rL2K3+F7W8m7zLm6jEeBxkZJzXsteHftY/8AIn6N/wBhBKAR6l4A/wCRI0L/AK84v/QRW/VLRf8AkD2H/XvH/wCgirtADl6V8q/tz/8AMk/9v3/tvX1UvSvlX9uf/mSf+37/ANt6Yz6A+E//ACSzwb/2BbL/ANEJXVN0rlfhP/ySzwb/ANgWy/8ARCV1TdKAG0UUUhHC/HCaOH4VeI/NkVA1sVXccZJIwPrVT9nz/kkegf8AXM/+hGqX7Sp/4tHq3s0f866D4PW0Vr8M/DyQIEQ2qsQPU9TQB2VFFFABWB49lkh8Fa3JC7RyLZyFWU4I+U1v1zHxNuIrX4f6/NcOEjFpICx9xgUAcB+yrZfZ/hobrzC7Xd1I5BH3ccde9ezV5L+y/wAfCSyB6/aJf5ivWqACnU2nUIEDdK5Pwb/yMXjv/sMx/wDpus66xulcn4N/5GLx3/2GY/8A03WdAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4D+1ZLbSp4SspWVpHvtxjPUocAmvfq+e/jm8mo/GPwJplvbmSVJBL1GGG7pg+mKBo99sIkhsreOJdqJGqqPQADFT0UUCCiiigDA8fXUtl4J1u4tyBLHaSFSRkfdrzj9lS0lh+GjXEhQrdXUki7TyPrXY/Ge8ksPhh4hnhCFxbFcMCRzx/Wsf9nKyksfhLo4kKnzi8y7T0BPAPvxQM9NooooEFFFFABXK/Fj/AJJZ4y/7A15/6Ieuqrlfix/ySzxl/wBga8/9EPQB1VFFFABRRRQAUUUUAeD/ALWc6Hwzodjsd5ri+BQBcg46ivaPD8C2uh6fAkQiEdvGuwLjb8o4xXiH7Rplv/HHgPSFKJHLc+aHK5IbcB+WBXvyjCgegoGLRRRQIK8C/avkuJrPwvp8G0rcXvQ8EsMY57V77Xgv7Tf/ACFPA/8A2EB/MUDR7hpcTQ6baRSDDpCisAc4IUA1apF+6PpS0CHL0r5V/bn/AOZJ/wC37/23r6qXpXyr+3P/AMyT/wBv3/tvTGfQHwn/AOSWeDf+wLZf+iErqm6Vyvwn/wCSWeDf+wLZf+iErqm6UANooopCPG/2qppY/hj5cUjKs13GjgfxDnivQ/h/ZHTvBGh2hkEnl2cY3YxnK56fjXmH7Wd2I/AunWmx2kub1dpXttGf1r17wyCvhzSlYFWFrECCMEfKKYzSooopCCuG+OH/ACSjxJ/16n+Yrua4b43/APJKPEn/AF6n+YoAo/s9wRQfCXQjDGqGSNnfH8TEnJNej1578Af+SSeHv+uJ/ma9CoAKdTadQgQN0rk/Bv8AyMXjv/sMx/8Apus66xulcn4N/wCRi8d/9hmP/wBN1nQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfP3idJdS/ao0S3eYLHZWyzINoPG0kj8fWvoAivnvwEserftM+J76KBpIbSNk8xl/1bcD9aAPoWiiigAooooA8x/aQvJLP4S6sYgp81kibcM/KTzj34ra+Ddm9h8MfD0ErKzC1VsrnHPP8AWuK/atuJo/hzDbxPtjuLxEkGAcivT/BVn/Z/hHRrXzPM8q0jG7GM/KD0oGbVFFFAgooooAK5X4sf8ks8Zf8AYGvP/RD11Vcr8WP+SWeMv+wNef8Aoh6AOqooooAKKKKACiikNAHz343WPV/2nfDlosLzraQq8ylTheCQ34etfQtfPfhQtqv7UmuXDXKutjAyIFAORgDbkelfQlA2FFFFAhK+fP2jhdXnxA8CabAylXmEiq2B828c5+gr6ErwT44/8lj+HX/XQ/8AodAI96XoPXFLRRQA5elfKv7c/wDzJP8A2/f+29fVS9K+Vf25/wDmSf8At+/9t6Yz6A+E/wDySzwb/wBgWy/9EJXVN0rlfhP/AMks8G/9gWy/9EJXVN0oAbRRRSEeD/tVyR/YPCkW9fN/tINsyM445x6V7lZf8ecH/XNf5V4v8f8AwzqWu+KPBs1npdzfWEFyBctChYICw+8ByB717YiBEVV4VRgD0FADqKKKACvNv2iL17L4TayY1VvOCwnd2DHkj3r0muC+N3h3U/FXw9vtK0SJJr6V0ZEeQIDg88nigCL4A/8AJJPD3/XE/wDoRr0KuZ+G+hSeG/BGj6VOnlz20AWVN+/Dd+e9dNQAU6m06hAgbpXJ+Df+Ri8d/wDYZj/9N1nXWN0rk/Bv/IxeO/8AsMx/+m6zoA6qiiigAooooAKKKKACiiigAooooAKKKKAGuwRGZmCqoySeABXgH7OO7UvHPjvWZJVZ5LjysIo2kbiQwOfavddYSWTSrxLaLzZnhdUTcF3EggDJ6V5p+z74L1bwboeqReILOC2vbq6Mo8uRZCU7AsPSmM9XooopCCkpaKAPBv2q989j4Vs/NdILi/2uFPB6YP1Ga9x0+EW1hbQKSViiVAT1IAArz34nfDifxt4k8Pah9vigtNMk3y28iM3nfNnggjFekgAAAdBxQMWiiigQUUUUAFcr8WP+SWeMv+wNef8Aoh66quV+LH/JLPGX/YGvP/RD0AdVRRRQAUUUUAFNc7VLYzgZp1UNdE50S/W0iM1w0DiONWClmKkAAnpQB4b+zkjah458day0UaI9yYgucsp3H26cV9A15B+zh4V1Twz4c1P+3tNlsNQubsuRKwZnXscgkV6/QwYUUUUAJXzv8Yrme7+PvgmxSLctuUddgJY5bJzX0TXiPi7RtTuP2jfDWpQadeSadDABJdJCxiQ88F8YFAHt1FFFADl6V8q/tz/8yT/2/f8AtvX1UvSvlX9uf/mSf+37/wBt6Yz6A+E//JLPBv8A2BbL/wBEJXVN0ry/4ZePvB1n8NvCdreeLPD8FzBpNpHLFLqMKPG6woCrAtkEEEEGulPxG8EY/wCRy8N/+DSD/wCKoA6miuV/4WN4I/6HLw3/AODSD/4qj/hY3gj/AKHLw3/4NIP/AIqkI6qiuV/4WN4I/wChy8N/+DSD/wCKo/4WN4I/6HLw3/4NIP8A4qgDqqK5X/hY3gj/AKHLw3/4NIP/AIqj/hY3gj/ocvDf/g0g/wDiqAOqorlf+FjeCP8AocvDf/g0g/8AiqP+FjeCP+hy8N/+DSD/AOKoA6qiuV/4WN4I/wChy8N/+DSD/wCKo/4WN4I/6HLw3/4NIP8A4qgDqqdXJ/8ACxvBH/Q5eG//AAaQf/FU7/hY/gf/AKHLw3/4NIP/AIqgDqm6Vyfg3/kYvHf/AGGY/wD03WdKfiN4Ix/yOXhv/wAGkH/xVcz4U8feD4Ne8ZyTeK/D8cdxq0ckLPqMIEiCxtF3Kd3I3Ky5HdSOxoA9Porlf+FjeCP+hy8N/wDg0g/+Ko/4WN4I/wChy8N/+DSD/wCKoA6qiuV/4WN4I/6HLw3/AODSD/4qj/hY3gj/AKHLw3/4NIP/AIqgDqqK5X/hY3gj/ocvDf8A4NIP/iqP+FjeCP8AocvDf/g0g/8AiqAOqorlf+FjeCP+hy8N/wDg0g/+Ko/4WN4I/wChy8N/+DSD/wCKoA6qiuV/4WN4I/6HLw3/AODSD/4qj/hY3gj/AKHLw3/4NIP/AIqgDqqK5X/hY3gj/ocvDf8A4NIP/iqP+FjeCP8AocvDf/g0g/8AiqAOqorlf+FjeCP+hy8N/wDg0g/+Ko/4WN4I/wChy8N/+DSD/wCKoA6qiuV/4WN4I/6HLw3/AODSD/4qj/hY3gj/AKHLw3/4NIP/AIqgDqqK5X/hY3gj/ocvDf8A4NIP/iqP+FjeCP8AocvDf/g0g/8AiqAOqorlf+FjeCP+hy8N/wDg0g/+Ko/4WN4I/wChy8N/+DSD/wCKoA6qiuV/4WN4I/6HLw3/AODSD/4qj/hY3gj/AKHLw3/4NIP/AIqgDqqK5X/hY3gj/ocvDf8A4NIP/iqP+FjeCP8AocvDf/g0g/8AiqAOqrlfix/ySzxl/wBga8/9EPR/wsbwR/0OXhv/AMGkH/xVc18TfHvg+8+G/iu2tPFfh+e5n0m7jihi1GFnkcwuAqgNkkkgACgD0+iuV/4WN4I/6HLw3/4NIP8A4qj/AIWN4I/6HLw3/wCDSD/4qgDqqK5X/hY3gj/ocvDf/g0g/wDiqP8AhY3gj/ocvDf/AINIP/iqAOqorlf+FjeCP+hy8N/+DSD/AOKo/wCFjeCP+hy8N/8Ag0g/+KoA6nFLXK/8LG8Ef9Dl4b/8GkH/AMVR/wALG8Ef9Dl4b/8ABpB/8VQB1VFcr/wsbwR/0OXhv/waQf8AxVH/AAsbwR/0OXhv/wAGkH/xVAHVUmOK5b/hY3gj/ocvDf8A4NIP/iqP+FjeCP8AocvDf/g0g/8AiqAOqorlf+FjeCP+hy8N/wDg0g/+Ko/4WN4I/wChy8N/+DSD/wCKoA6xelfKv7c//Mk/9v3/ALb17+PiP4Ix/wAjl4b/APBpB/8AFV81/tleI9D8Qf8ACIf2DrOm6n5H2zzfsV0k/l7vI27tpOM4OM9cGmM+lfhP/wAks8G/9gWy/wDRCV1Vcr8J/wDklng3/sC2X/ohK6qgAxRiiigAxRiiigAxRiisCDxfo8/iuXw3HJeHWIk814jYXCoqc4fzCmzadpAO7BIwMnigDfxRiiigAxRiiigAxRRRQAVyvg3/AJGLx3/2GY//AE3WddVXK+Df+Rj8d/8AYaj/APTdZ0AdVijFFFABijFFFABijFFFABijFFFABijFFFABijFFYXirxZpHhVbJtaku41vJRBAYLGe53yEgKn7pGwzEgKDgtzjODQBu4oxXPXnjLRrPxDYaHcPfLqd8u+3iGnXDB14yd4j2gLuG7JG3PzYroaADFGKKKADFGKKKADFGKKKADFGKKKADFGKKKADFcr8WP+SWeMv+wNe/+iHrqq5X4sf8ks8Zf9gW9/8ARD0AdVijFFFABijFFFABijFFFABijFNlkEUTyMGKoCxCqWPHoByT7CuRg+JHhqfQtS1mO41D+zdOcx3UzaVdr5TAkMCDFk7dp3YHy/xYoA7DFGK5O4+IPh63/sjzpNTU6v8A8eS/2Td5mPPGPKyDhS2Dg7fm6EGusoAMUYoooAMUYoooAK+Vf25/+ZJ/7fv/AG3r6qr5V/bn/wCZJ/7fv/begD6A+E//ACSzwb/2BbL/ANEJXVVyvwn/AOSWeDf+wLZf+iErqqACiiigAooooAK8t0zWNMf9orWLVNRs2um0K3gEInUuZFmmdk25zuCkMR1AOa9SooAKKKKACiiigAooooAK5Xwb/wAjH47/AOw1H/6brOuqrlfBv/Ix+O/+w1H/AOm6zoA6qiiigAooooAKKKKACiiigAooooAK8v8AjzqunadZ+D11G/tLQnxJYTgTzLHmOOZTI/J+6oILHoMjNeoUUAeV+Kdc0lfjp4GibVLESmwvU2G4QHdL5PlDGer4O3+9jjNeqUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxY/5JZ4y/7At7/wCiHrqq5X4sf8ks8Zf9gW9/9EPQB1VFFFABRRRQAUUUUANlkSGJ5JXVI0BZnY4CgdST2FfPWn+INGk+BXxOEeraexe81YLtuUO7znk8rHP8f8P97tmvoeigDw/xH4k0M3/wekGs6YYxP5hf7UmAv2Z492c9N4KZ/vcda9woooAKKKKACiiigAr5V/bn/wCZJ/7fv/bevqqvlX9uf/mSf+37/wBt6APoL4WRyQ/DHwhFMjRyJo9mrIwwVIhQEEdjXUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcv4QjdPEHjdnRlWTWI2QkYDD+z7MZHqMgj8DRRQB1FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcv8U45Jvhj4vihRpJH0e8VUUZLEwuAAO5oooA6iiiigAooooAKKKKACiiigAooooAKKKKACiiigAr5g/bY02+1D/hDPsFnc3Wz7bv8AJiZ9ufIxnA46H8qKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radial neck angulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33296=[""].join("\n");
var outline_f32_33_33296=null;
var title_f32_33_33297="Supraspinatus active abduction";
var content_f32_33_33297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Supraspinatus active abduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Start in a standing position with both arms fully extended at the elbow, arms at a 45 degree angle from the body and thumbs pointing up to the sky. Raise both arms to the height of the shoulder on a 2 count, slowly return to the starting position on a 4 count, and repeat for a total of 15 repetitions. Make sure to lift from the shoulder; do not allow the shoulder blades to shrug upwards. Rest for 30 seconds and repeat for a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33297=[""].join("\n");
var outline_f32_33_33297=null;
var title_f32_33_33298="Two piece penile prosthesis";
var content_f32_33_33298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Two-piece penile prosthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of American Medical Systems, Inc. Minnetonka, Minnesota (www.AmericanMedicalSystems.com).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33298=[""].join("\n");
var outline_f32_33_33298=null;
var title_f32_33_33299="Sodium phenylacetate and sodium benzoate: Patient drug information";
var content_f32_33_33299=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium phenylacetate and sodium benzoate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/21/7509?source=see_link\">",
"     see \"Sodium phenylacetate and sodium benzoate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/32/2565?source=see_link\">",
"     see \"Sodium phenylacetate and sodium benzoate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ammonul&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat urea cycle problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702943",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium phenylacetate, sodium benzoate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12123 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33299=[""].join("\n");
var outline_f32_33_33299=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221922\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018130\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018129\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018134\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018135\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018137\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018132\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018139\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/21/7509?source=related_link\">",
"      Sodium phenylacetate and sodium benzoate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/32/2565?source=related_link\">",
"      Sodium phenylacetate and sodium benzoate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_33_33300="Fibrin plug eso varix Endosc";
var content_f32_33_33300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53168%7EGAST%2F50222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53168%7EGAST%2F50222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Fibrin plug on an esophageal varix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Upper endoscopy reveals two chains of varices (9 and 5 o'clock). A yellowish fibrin plug is visible in the 9 o'clock varix indicating the site of recent bleeding. Right panel: Close-up view of the fibrin plug.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic \"red wale\" sign on esophageal varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy of a chain of varices in the distal esophagus showing erythematous raised areas indicating an increased risk of bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33300=[""].join("\n");
var outline_f32_33_33300=null;
var title_f32_33_33301="Viral exanthem close view";
var content_f32_33_33301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Viral exanthem",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules are present on the skin of this patient with a viral exanthem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33301=[""].join("\n");
var outline_f32_33_33301=null;
var title_f32_33_33302="Epidemiology and clinical manifestations of Penicillium marneffei infection";
var content_f32_33_33302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of Penicillium marneffei infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Khuanchai Supparatpinyo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Thira Sirisanthana, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33302/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/33/33302/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillium marneffei is an important cause of morbidity and mortality in HIV-infected patients in Southeast Asia and occasionally in immunosuppressed patients who have had travel-related exposure to this organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This systemic fungal infection was commonly diagnosed prior to the era of potent antiretroviral therapy (ART). The widespread use of ART has led to a significant decline of opportunistic infections (OIs), including P. marneffei, in areas of high endemicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/2\">",
"     2",
"    </a>",
"    ]. However, despite the wide availability of potent ART in Thailand, P. marneffei infection continues to cause considerable morbidity and mortality in AIDS patients who are either unaware of their HIV infection, who do not have access to ART, or who have suboptimal treatment responses.",
"   </p>",
"   <p>",
"    The mycology, epidemiology, and clinical manifestations of P. marneffei will be reviewed here. The diagnosis and treatment of this infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/35/15928?source=see_link\">",
"     \"Diagnosis and treatment of Penicillium marneffei infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other fungal pulmonary pathogens, such as Cryptococcosis, Aspergillus spp., Fusarium spp., agents of Mucormycosis, and Scedosporium spp., are discussed elsewhere. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. marneffei was first isolated from the bamboo rat (Rhizomys sinensis) in Vietnam in 1956 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/3\">",
"     3",
"    </a>",
"    ]. The first human case was reported in an American missionary with Hodgkin disease who had been living in Southeast Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/4\">",
"     4",
"    </a>",
"    ]. Thereafter, rare cases of P. marneffei infection were reported mostly from Southeast Asia and Southern China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The first case of P. marneffei infection in an HIV-infected patient was reported in 1989 from Bangkok, coinciding with the beginning of the AIDS epidemic in the region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MYCOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. marneffei is the only species of the genus Penicillium that is a dimorphic fungus. The organism typically takes about four to seven days to grow in culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    P. marneffei grows as a mold at 25&ordm;C on Sabouraud dextrose agar; aged colonies produce a soluble red pigment that diffuses into the agar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/8\">",
"     8",
"    </a>",
"    ]. &nbsp;Microscopically, the mycelia show typical structures of Penicillium species, including septate hyphae with lateral and terminal conidiophores (ie, penicillii) (",
"    <a class=\"graphic graphic_picture graphicRef78922 \" href=\"mobipreview.htm?23/62/24544\">",
"     picture 1",
"    </a>",
"    ). When transferred to brain-heart infusion agar and incubated at 37&ordm;C, white to tan-colored colonies of the yeast develop within a few days (",
"    <a class=\"graphic graphic_picture graphicRef52809 \" href=\"mobipreview.htm?15/8/15490\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The yeast cells are round to oval with a central septum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/4,5,9\">",
"     4,5,9",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef61201 \" href=\"mobipreview.htm?11/54/12143\">",
"     picture 3",
"    </a>",
"    ). However, analysis of the complete genome demonstrates that P. marneffei is more closely related to molds than yeasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endemicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. marneffei is endemic in most countries in Southeast Asia, Northeastern India, Southern China, Hong Kong, and Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/9,11-16\">",
"     9,11-16",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef70028 \" href=\"mobipreview.htm?15/35/15922\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In northern Thailand, P. marneffei is the fourth most common opportunistic infection, following tuberculosis, extrapulmonary cryptococcal infection, and pneumocystis pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/17\">",
"     17",
"    </a>",
"    ]. Between 1991 and 2004, more than 6000 cases of P. marneffei infection in HIV-infected patients were reported to the Thai Ministry of Public Health. As the",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    epidemic spread, the prevalence of P. marneffei infection also increased in other countries in the region (Vietnam, India, Taiwan, Malaysia, Cambodia, and the provinces of Guangxi and Guangdong of China) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Cases of disseminated P. marneffei infection have also been reported in HIV-infected patients from the United States, Europe, Japan, and Australia following visits to endemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Penicillium species, other than marneffei, rarely cause infection; only about 30 cases have been reported from around the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Potential reservoirs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many aspects of ecology of P. marneffei and its relationship to human infection remain unknown. Humans and bamboo rats are the only known animal hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/21\">",
"     21",
"    </a>",
"    ]. Although the geographic habitats of these bamboo rats correspond with the regional areas where human cases of P. marneffei infection have been found, definite proof of an environmental reservoir for P. marneffei, within the soil or other substrates, is still lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies of HIV-infected patients with advanced immunosuppression in Thailand suggest an association between Penicillium infection and soil exposure, especially during the rainy season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]. For example, in two epidemiologic studies from Chiang Mai, identification of patients with disseminated P. marneffei infection significantly increased during the rainy season, whereas cases of cryptococcal infection were steady throughout the year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/23\">",
"     23",
"    </a>",
"    ]. In another case-control study of 240 AIDS patients, 80 of whom had P. marneffei infection, cases were more likely than controls to have a recent history of occupational or other exposure to soil, particularly during the rainy season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/24\">",
"     24",
"    </a>",
"    ]. These observations suggest that there may be seasonal expansion of the environmental reservoir whereby both humans and bamboo rats acquire the fungus from a common reservoir. However, attempts to isolate the fungus from soil, bamboo, or vegetation have yielded negative results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of transmission of P. marneffei is still unknown. Similar to other endemic fungi (eg, Coccidioides and Histoplasma) an airborne route is suspected via inhalation of conidia from an environmental reservoir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/5\">",
"     5",
"    </a>",
"    ]. In one case report, an HIV-infected physician, who had never previously visited an endemic area, developed P. marneffei infection shortly after entering a mycology class on the morphologic identification of P. marneffei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/26\">",
"     26",
"    </a>",
"    ]. However, air samples taken in the building did not yield any organisms.",
"   </p>",
"   <p>",
"    Inoculation of skin wounds can cause localized disease. This evidence was from the first reported case of human infection in 1959 due to a P. marneffei-contaminated needle stick injury in the mycology lab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subclinical infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;By analogy to histoplasmosis, it is likely that subclinical infection may occur commonly in persons living in endemic areas who are exposed to P. marneffei in the environment. In one study in northern Thailand, about 10 percent of the population had latent P. marneffei infection by Western immunoblot testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/28\">",
"     28",
"    </a>",
"    ]. The existence of latent infection in humans is also supported by a case report from Australia of an HIV-infected patient who had a 10-year period between probable exposure and onset of clinical infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated P. marneffei infection develops in immunocompromised individuals, especially those with HIV infection and other acquired cellular immune deficits (hematologic malignancies, transplant patients, and those treated with steroids or cytotoxic agents) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. marneffei infection usually occurs late in the course of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. The majority of cases are observed in patients who have a CD4+ cell count of &lt;100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients commonly present with symptoms and signs of infection of the reticuloendothelial system, including generalized lymphadenopathy, hepatomegaly, and splenomegaly (",
"    <a class=\"graphic graphic_table graphicRef68332 \" href=\"mobipreview.htm?10/43/10940\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/9,13,15\">",
"     9,13,15",
"    </a>",
"    ]. The respiratory system is commonly involved as well; cough, fever, dyspnea, and chest pain may be present, reflecting the probable inhalational route of acquisition. Approximately one-third of patients may also exhibit gastrointestinal symptoms, such as diarrhea (",
"    <a class=\"graphic graphic_table graphicRef68332 \" href=\"mobipreview.htm?10/43/10940\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fungemia can also lead to skin lesions, arthritis, and osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/15\">",
"     15",
"    </a>",
"    ]. Skin lesions are seen in approximately 70 percent of patients, and, when present, are the best clues to the diagnosis. They are usually found as papules on the face, chest, and extremities. The center of the papule subsequently becomes necrotic, giving the appearance of an umbilicated papule, which can resemble molluscum contagiosum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/34\">",
"     34",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef76286 \" href=\"mobipreview.htm?27/48/28420\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80674 \" href=\"mobipreview.htm?16/24/16770\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56450 \" href=\"mobipreview.htm?10/46/10980\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6842?source=see_link\">",
"     \"Molluscum contagiosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations associated with late HIV infection, such as anorexia, asthenia, anemia, weight loss, and cachexia, are also seen in the majority of the patients.",
"   </p>",
"   <p>",
"    Atypical pulmonary presentations have also been reported, including single or multiple cavitary lesions and a lung mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Surgery for clinical diagnoses of peritonitis and appendicitis were performed in three children, who were later diagnosed with mesenteric adenitis; all had positive blood and bone marrow cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/37\">",
"     37",
"    </a>",
"    ]. P. marneffei was also demonstrated in the liver and cultured from the blood from six patients who presented with fever, hepatomegaly, and markedly elevated serum alkaline phosphatase levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/38\">",
"     38",
"    </a>",
"    ]. Mucosal lesions in the oral cavity, oropharynx, hypopharynx, stomach, colon, and genitalia have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/9,39-41\">",
"     9,39-41",
"    </a>",
"    ]. The first case series of patients presenting with a syndrome characterized by acute onset of altered mental status, fever, and nonspecific constitutional symptoms was described in Vietnam; all had Penicillium isolated from their cerebral spinal fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is seen in about 75 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef68332 \" href=\"mobipreview.htm?10/43/10940\">",
"     table 1",
"    </a>",
"    ). Other hematologic and biochemical laboratory values are rather non-specific and may include mild elevations of aminotransferases and bilirubin, and leukocytosis or leucopenia. These non-specific abnormal findings can be found in about one-third to 50 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings are diverse; chest radiography may show diffuse reticulonodular, localized alveolar, or diffuse alveolar infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/13\">",
"     13",
"    </a>",
"    ]. Clinical features in children are similar to those seen in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33302/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penicillium marneffei is an important cause of morbidity and mortality in HIV-infected patients in Southeast Asia and occasionally in immunosuppressed patients who have had travel-related exposure to this organism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      P. marneffei is the only species of the genus Penicillium that is a dimorphic fungus. The organism typically takes about four to seven days to grow in culture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mycology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the mode of transmission of P. marneffei is unknown, an airborne route via inhalation of conidia from an environmental reservoir is suspected. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disseminated P. marneffei infection develops mainly in immunocompromised individuals, especially those with HIV infection and other acquired cellular immune deficits. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common clinical signs and symptoms of disseminated disease include fever, weight loss, non-productive cough, skin lesions, hepatosplenomegaly, and generalized lymphadenopathy. Anemia is the most common laboratory finding. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/1\">",
"      Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 Suppl 1:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/2\">",
"      Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis 2011; 52:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/3\">",
"      CAPPONI M, SEGRETAIN G, SUREAU P. [Penicillosis from Rhizomys sinensis]. Bull Soc Pathol Exot Filiales 1956; 49:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/4\">",
"      DiSalvo AF, Fickling AM, Ajello L. Infection caused by Penicillium marneffei: description of first natural infection in man. Am J Clin Pathol 1973; 60:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/5\">",
"      Jayanetra P, Nitiyanant P, Ajello L, et al. Penicilliosis marneffei in Thailand: report of five human cases. Am J Trop Med Hyg 1984; 33:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/6\">",
"      Deng ZL, Yun M, Ajello L. Human penicilliosis marneffei and its relation to the bamboo rat (Rhizomys pruinosus). J Med Vet Mycol 1986; 24:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/7\">",
"      Sathapatayavongs B, Damrongkitchaiporn S, Saengditha P, et al. Disseminated penicilliosis associated with HIV infection. J Infect 1989; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/8\">",
"      Vanittanakom N, Vanittanakom P, Hay RJ. Rapid identification of Penicillium marneffei by PCR-based detection of specific sequences on the rRNA gene. J Clin Microbiol 2002; 40:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/9\">",
"      Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/10\">",
"      Woo PC, Zhen H, Cai JJ, et al. The mitochondrial genome of the thermal dimorphic fungus Penicillium marneffei is more closely related to those of molds than yeasts. FEBS Lett 2003; 555:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/11\">",
"      Deng Z, Ribas JL, Gibson DW, Connor DH. Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis 1988; 10:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/12\">",
"      Clezy K, Sirisanthana T, Sirisanthana V, et al. Late manifestations of HIV in Asia and the Pacific. AIDS 1994; 8 Suppl 2:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/13\">",
"      Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/14\">",
"      Singh PN, Ranjana K, Singh YI, et al. Indigenous disseminated Penicillium marneffei infection in the state of Manipur, India: report of four autochthonous cases. J Clin Microbiol 1999; 37:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/15\">",
"      Louthrenoo W, Thamprasert K, Sirisanthana T. Osteoarticular penicilliosis marneffei. A report of eight cases and review of the literature. Br J Rheumatol 1994; 33:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/16\">",
"      Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect 2002; 45:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/17\">",
"      Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994--1998: regional variation and temporal trends. Clin Infect Dis 2001; 32:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/18\">",
"      Huynh TX, Nguyen HC, Dinh Nguyen HM, et al. [Penicillium marneffei infection and AIDS. A review of 12 cases reported in the Tropical Diseases Centre, Ho Chi Minh City (Vietnam)]. Sante 2003; 13:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/19\">",
"      Vanittanakom N, Sirisanthana T. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Curr Top Med Mycol 1997; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/20\">",
"      Lyratzopoulos G, Ellis M, Nerringer R, Denning DW. Invasive infection due to penicillium species other than P. marneffei. J Infect 2002; 45:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/21\">",
"      Gugnani H, Fisher MC, Paliwal-Johsi A, et al. Role of Cannomys badius as a natural animal host of Penicillium marneffei in India. J Clin Microbiol 2004; 42:5070.",
"     </a>",
"    </li>",
"    <li>",
"     Corbet GB, Hill JE. Subfamily Rhizomyinae: bamboo rats. In: The Mammals of the Indo Malaya Region: A Systematic Review, Oxford University Press, Oxford, UK 1992. p.404.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/23\">",
"      Chariyalertsak S, Sirisanthana T, Supparatpinyo K, Nelson KE. Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir? J Infect Dis 1996; 173:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/24\">",
"      Chariyalertsak S, Sirisanthana T, Supparatpinyo K, et al. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand. Clin Infect Dis 1997; 24:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/25\">",
"      Chariyalertsak S, Vanittanakom P, Nelson KE, et al. Rhizomys sumatrensis and Cannomys badius, new natural animal hosts of Penicillium marneffei. J Med Vet Mycol 1996; 34:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/26\">",
"      Hilmarsdottir I, Coutellier A, Elbaz J, et al. A French case of laboratory-acquired disseminated Penicillium marneffei infection in a patient with AIDS. Clin Infect Dis 1994; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/27\">",
"      SEGRETAIN G. [Penicillium marneffei n.sp., agent of a mycosis of the reticuloendothelial system]. Mycopathologia 1959; 11:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/28\">",
"      Vanittanakom N, Mekaprateep M, Sittisombut N, et al. Western immunoblot analysis of protein antigens of Penicillium marneffei. J Med Vet Mycol 1997; 35:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/29\">",
"      Jones PD, See J. Penicillium marneffei infection in patients infected with human immunodeficiency virus: late presentation in an area of nonendemicity. Clin Infect Dis 1992; 15:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/30\">",
"      Chan YH, Wong KM, Lee KC, et al. Pneumonia and mesenteric lymphadenopathy caused by disseminated Penicillium marneffei infection in a cadaveric renal transplant recipient. Transpl Infect Dis 2004; 6:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/31\">",
"      Wong SS, Wong KH, Hui WT, et al. Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiency virus (HIV)- and non-HIV-infected patients. J Clin Microbiol 2001; 39:4535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/32\">",
"      Tsang DN, Chan JK, Lau YT, et al. Penicillium marneffei infection: an underdiagnosed disease? Histopathology 1988; 13:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/33\">",
"      Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/34\">",
"      Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/35\">",
"      McShane H, Tang CM, Conlon CP. Disseminated Penicillium marneffei infection presenting as a right upper lobe mass in an HIV positive patient. Thorax 1998; 53:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/36\">",
"      Cheng NC, Wong WW, Fung CP, Liu CY. Unusual pulmonary manifestations of disseminated Penicillium marneffei infection in three AIDS patients. Med Mycol 1998; 36:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/37\">",
"      Ukarapol N, Sirisanthana V, Wongsawasdi L. Penicillium marneffei mesenteric lymphadenitis in human immunodeficiency virus-infected children. J Med Assoc Thai 1998; 81:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/38\">",
"      Kantipong P, Panich V, Pongsurachet V, Watt G. Hepatic penicilliosis in patients without skin lesions. Clin Infect Dis 1998; 26:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/39\">",
"      Tong AC, Wong M, Smith NJ. Penicillium marneffei infection presenting as oral ulcerations in a patient infected with human immunodeficiency virus. J Oral Maxillofac Surg 2001; 59:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/40\">",
"      Kronauer CM, Sch&auml;r G, Barben M, B&uuml;hler H. [HIV-associated Penicillium marneffei infection]. Schweiz Med Wochenschr 1993; 123:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/41\">",
"      Leung R, Sung JY, Chow J, Lai CK. Unusual cause of fever and diarrhea in a patient with AIDS. Penicillium marneffei infection. Dig Dis Sci 1996; 41:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/42\">",
"      Le T, Huu Chi N, Kim Cuc NT, et al. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis 2010; 51:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33302/abstract/43\">",
"      Sirisanthana V, Sirisanthana T. Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995; 14:935.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3033 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33302=[""].join("\n");
var outline_f32_33_33302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MYCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endemicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Potential reservoirs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subclinical infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3033|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/35/15922\" title=\"figure 1\">",
"      Endemic areas P marneffei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3033|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/62/24544\" title=\"picture 1\">",
"      Micro P marneffei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/8/15490\" title=\"picture 2\">",
"      Yeasts incubate agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/54/12143\" title=\"picture 3\">",
"      Micro P marneffei yeasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/48/28420\" title=\"picture 4\">",
"      Skin lesion HIV P marneffei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/24/16770\" title=\"picture 5\">",
"      Penicillium marneffei - papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/46/10980\" title=\"picture 6\">",
"      Penicillium marneffei papule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/43/10940\" title=\"table 1\">",
"      Clin manif HIV P marneffei",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/35/15928?source=related_link\">",
"      Diagnosis and treatment of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_33_33303="Pomalidomide: Drug information";
var content_f32_33_33303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pomalidomide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/5/42069?source=see_link\">",
"    see \"Pomalidomide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16146618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16226145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pomalyst&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16146639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiogenesis Inhibitor;",
"     </li>",
"     <li>",
"      Antineoplastic Agent;",
"     </li>",
"     <li>",
"      Immunomodulator, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16226173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     ANC should be &ge;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to initiating new cycles of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Multiple myeloma, relapsed/refractory",
"     </b>",
"     : Adults: Oral: 4 mg once daily on days 1-21 of 28-day cycles (may be given in combination with dexamethasone); continue until disease progression or unacceptable toxicity",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16226174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16226176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum creatinine &gt;3 mg/dL: Avoid use (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16226177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bilirubin &gt;2 mg/dL and AST/ALT &gt;3 times ULN: Avoid use (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F16226175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hematologic:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or ANC &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     with fever &ge;38.5&deg;C) and/or platelets &lt;25,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt therapy and follow weekly CBCs. When ANC &ge;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelets &ge;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume dosing at 3 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     For each subsequent drop of ANC &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelets &lt;25,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt therapy. When ANC &ge;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelets &ge;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Resume dosing at 1 mg less than the previous dose. If toxicities occur at 1 mg daily dose, discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Nonhematologic:",
"     </i>",
"     If grade 3 or 4 toxicity occurs, interrupt therapy until resolved to &le; grade 2; if appropriate, may restart therapy at 1 mg less than the previous dose. If toxicities occur at 1 mg daily dose, discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16253280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pomalyst&reg;: 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16226146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F16226144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Pomalidomide is approved for marketing in the U.S. only under a Food and Drug Administration (FDA) approved, restricted distribution program called Pomalyst REMS&trade; (celgeneriskmanagement.com or 1-888-423-5436). Physicians, pharmacies, and patients must be registered; a maximum 28-day supply may be dispensed; a new prescription is required each time it is filled; pregnancy testing is required for women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F16226142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM340163.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM340163.pdf",
"     </a>",
"     must be dispensed with this medication",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16226178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach with water (at least 2 hours before or 2 hours after a meal). Should be swallowed  whole; do not break, chew, or open the capsules.  May administer a missed dose if within 12 hours of usual dosing time. If &gt;12 hours, skip the dose for that day and resume usual dosing the following day. Do not take 2 doses to make up for a skipped dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16146620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of multiple myeloma in patients who have received at least two prior therapies (including lenalidomide and bortezomib) and have continued disease progression on or within 60 days of completion of the last therapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16226140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pomalidomide may be confused with lenalidomide, thalidomide",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16224392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (55%), dizziness (18% to 20%), fever (19%), neuropathy (18%), headache (13%), confusion (10% to 12%), anxiety (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin rash (22%), pruritus (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia (21%), hyperglycemia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (36%), nausea (36%), diarrhea (34%), decreased appetite (22%), vomiting (14%), weight loss (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic &amp; oncologic: Neutropenia (50% to 52%; grades 3/4: 43% to 47%), anemia (38%; grades 3/4: 22%), thrombocytopenia (25%; grades 3/4: 22%), leukopenia (11%; grades 3/4: 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Musculoskeletal: Back pain (32%), musculoskeletal chest pain (22%), muscle spasm (19%), arthralgia (16%), ostealgia (12%), myasthenia (12%), musculoskeletal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Increased serum creatinine (15%), renal failure (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (34%), upper respiratory tract infection (32%), pneumonia (23%), epistaxis (15%), cough (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Thrombosis (venous thrombosis, pulmonary embolism, 3%), atrial fibrillation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Peripheral neuropathy (10%), chills (9%), insomnia (7%), pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Xeroderma (9%), hyperhidrosis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (10%), hyponatremia (10%), hypocalcemia (6%), dehydration (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic &amp; oncologic: Lymphocytopenia (4%; grades 3/4: 2%), febrile neutropenia (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infection: Sepsis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Musculoskeletal: Tremor (9%), limb pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Night sweats (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined: Acute myelocytic leukemia, hyperbilirubinemia, hyperkalemia, increased serum ALT, interstitial pulmonary disease, neutropenic sepsis, pelvic pain,",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia, respiratory syncytial virus infection, urinary retention, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16226152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16226153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Neutropenia, anemia, and thrombocytopenia were frequently reported in clinical trials. Monitor complete blood counts weekly for the first 8 weeks of therapy and monthly or as clinically indicated thereafter; may require therapy interruption, reduction and/or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS effects: May cause dizziness and/or confusion; caution patients about performing tasks that require mental alertness (eg, operating machinery or driving). Avoid concomitant medications which may exacerbate dizziness and confusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Use with caution in patients with a prior history of serious hypersensitivity reactions to thalidomide or lenalidomide; such patients were excluded from pomalidomide clinical trials and may therefore be at risk for hypersensitivity reactions when administered pomalidomide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuropathy: Peripheral and sensory neuropathy occurred in clinical trials, but no cases of  grade 3 or higher neuropathy were observed. Monitor closely for signs/symptoms of neuropathy; may require therapy interruption, dose modification and/or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Secondary malignancy: Acute myelogenous leukemia (AML) as a secondary malignancy has been reported in patients receiving pomalidomide in the investigational treatment of condition(s) other than multiple myeloma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Venous thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) have occurred during pomalidomide therapy. Consider individualized anticoagulation prophylaxis based on patient risk factors.",
"     </b>",
"     Monitor for signs/symptoms of thromboembolism (shortness of breath, chest pain, or arm or leg swelling) and advise patients to promptly seek medical attention should symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been evaluated in patients with hepatic impairment. Pomalidomide is hepatically metabolized; avoid use in patients with serum bilirubin &gt;2 mg/dL and AST/ALT &gt;3 times ULN (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Safety and efficacy have not been evaluated in patients with renal impairment. Pomalidomide and its metabolites are excreted by the kidneys; avoid use in patients with serum creatinine &gt;3 mg/dL (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cigarette smokers: Cigarette smoking may induce CYP1A2 mediated metabolism of pomalidomide, potentially reducing its systemic exposure and efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Pomalidomide is a thalidomide (human teratogen) analog and may cause severe life-threatening birth defects or embryo-fetal deaths; use is contraindicated in pregnancy. Pregnancy must be excluded prior to therapy initiation with 2 negative pregnancy tests; prevent pregnancy during therapy with 2 reliable forms of contraception (or abstain from heterosexual intercourse) beginning 4 weeks prior to, during and for 4 weeks after pomalidomide therapy (and during treatment interruptions) in females of reproductive potential.",
"     </b>",
"     Males taking pomalidomide must use a latex or synthetic condom during any sexual contact with a woman of childbearing potential during therapy and for up to 28 days after treatment discontinuation, even if successfully vasectomized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blood donation: Patients should not donate blood during pomalidomide treatment and for 1 month after therapy discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Pomalidomide is only available through the restricted Pomalyst REMS&trade; program.",
"     </b>",
"     Pomalidomide should only be prescribed to patients who can understand and comply with the conditions of the Pomalyst REMS program. Prescribers and pharmacies must be certified with the REMS program.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sperm donation: Male patients receiving pomalidomide must not donate sperm.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16265541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16265539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Pomalidomide.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dexamethasone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16226148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16226149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      [U.S. Boxed Warning]: Pomalidomide is an analogue of thalidomide (a known human teratogen) and may cause severe birth defects or embryo-fetal death if taken during pregnancy. Pomalidomide cannot be used in women who are pregnant or may become pregnant during therapy. Obtain 2 negative pregnancy tests prior to initiation of treatment; 2 forms of contraception (or abstain from heterosexual intercourse) must be used at least 4 weeks prior to, during, and for &ge;4 weeks after pomalidomide treatment (and during treatment interruptions) in females of reproductive potential. Distribution is restricted; physicians, pharmacists, and patients must be registered with the Pomalyst&reg; REMS &trade; Program.",
"     </b>",
"     Studies in animals have shown evidence of fetal abnormalities and use is contraindicated in women who are or may become pregnant.  Women of childbearing potential should be treated only if they are able to comply with the conditions of the Pomalyst&reg; REMS &trade; Program. Reliable contraception is required even with a history of infertility (unless due to hysterectomy or if &ge;24 consecutive months postmenopausal (natural). Pregnancy tests should be performed 10-14 days and 24 hours prior to beginning therapy; weekly for the first 4 weeks and then every 4 weeks (every 2 weeks if menstrual cycle irregular) thereafter and during therapy interruptions. Pomalidomide must be immediately discontinued for a missed period, abnormal pregnancy test or abnormal menstrual bleeding; refer patient to a reproductive toxicity specialist if pregnancy occurs during treatment. Pomalidomide is present in the semen of males taking this medication. Males (including those vasectomized) should use a latex or synthetic condom during any sexual contact with women of childbearing age during treatment, during treatment interruptions, and for 28 days after discontinuation. Male patients should not donate sperm. Any suspected fetal exposure should be reported to the FDA via the MedWatch program (1-800-332-1088) and to Celgene Corporation (1-888-423-5436).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16226150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16226151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if pomalidomide is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue nursing or to discontinue treatment with pomalidomide, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F16226180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be taken on an empty stomach (at least 2 hours before or 2 hours after a meal)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Pomalyst Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (21): $12534.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (21): $12534.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (21): $12534.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (21): $12534.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16226181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets weekly for the first 8 weeks and monthly or as clinically necessary thereafter; serum creatinine; liver function tests; monitor for signs/symptoms of thromboembolism and neuropathy. Consider thyroid function tests (TSH recommended at baseline and every 2-3 months during treatment for structurally similar medications [Hamnvik, 2011]).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women of childbearing potential: Pregnancy test 10-14 days",
"     <b>",
"      and",
"     </b>",
"     24 hours prior to initiating therapy, weekly during the first month, then monthly thereafter in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16226160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces cell cycle arrest and apoptosis directly in multiple myeloma cells; enhances T cell- and natural killer (NK) cell-mediated cytotoxicity; inhibits production of proinflammatory cytokines tumor necrosis factor-&alpha; (TNF-&alpha;), IL-1, IL-6, and IL-12; inhibits angiogenesis (Zhu, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16226162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 62-138L; semen distribution is ~67% of plasma levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 12% to 44%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP1A2 and CYP3A4 (major); CYP2C19 and CYP2D6 (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~9.5 hours (healthy subjects); ~7.5 hours (multiple myeloma patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (73%; 2% as unchanged drug); feces (15%; 8% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/33/33303/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lacy MQ, Allred JB, Gertz MA, et al, &ldquo;Pomalidomide Plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of 2 Dosing Strategies in Dual-Refractory Disease,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(11):2970-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/33/33303/abstract-text/21690557/pubmed\" id=\"21690557\" target=\"_blank\">",
"        21690557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lacy MQ, Hayman SR, Gertz MA, et al, &ldquo;Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/Dex) is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM),&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2010, 24(11):1934-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/33/33303/abstract-text/20827286/pubmed\" id=\"20827286\" target=\"_blank\">",
"        20827286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leleu X, Attal M, Arnulf B, et al, &ldquo;Pomalidomide Plus Low Dose Dexamethasone is Active and Well Tolerated in Bortezomib and Lenalidomide Refractory Multiple Myeloma: IFM 2009-02,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2013,121(11):1968-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/33/33303/abstract-text/23319574/pubmed\" id=\"23319574\" target=\"_blank\">",
"        23319574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richardson PG, Siegel D, Baz R, et al, &ldquo;Phase I Study of Pomalidomide MTD, Safety and Efficacy in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2013, 121(11):1961-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/33/33303/abstract-text/23243282/pubmed\" id=\"23243282\" target=\"_blank\">",
"        23243282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhu YX, Kortuem KM, and Stewart AK, &ldquo;Molecular Mechanism of Action of Immune-Modulatory Drugs Thalidomide, Lenalidomide and Pomalidomide in Multiple Myeloma,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 2013, 54(4):683-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/33/33303/abstract-text/22966948/pubmed\" id=\"22966948\" target=\"_blank\">",
"        22966948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88099 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33303=[""].join("\n");
var outline_f32_33_33303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16146618\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16146639\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226173\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226174\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226176\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226177\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226175\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16253280\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226146\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226144\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226142\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226178\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16146620\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226140\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16224392\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226152\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226153\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265541\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226150\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226151\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226180\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570471\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226181\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226160\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226162\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88099\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88099|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/5/42069?source=related_link\">",
"      Pomalidomide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_33_33304="Human metapneumovirus infections";
var content_f32_33_33304=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human metapneumovirus infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     James E Crowe, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33304/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/33/33304/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory tract infections commonly are caused by viral pathogens, especially in young children. Respiratory syncytial virus (RSV) is the most common pathogen identified in these infections, followed historically by parainfluenza virus (PIV); both of these viruses are in the Paramyxoviridae family. Other important viruses that cause respiratory tract infection include influenza and adenoviruses. However, despite improved methods for identifying viral pathogens in these infections, the etiology remains undetermined in a significant number of patients.",
"   </p>",
"   <p>",
"    In 2001, investigators from the Netherlands discovered a new member of the Paramyxoviridae family in the genus Metapneumovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ]. The first representative of this genus to cause infection in humans has been called the human metapneumovirus (hMPV). Data suggest this virus has been responsible for respiratory tract infections for at least 60 years with a worldwide distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virology, pathogenesis, epidemiology, clinical manifestations, diagnosis, and treatment of hMPV will be discussed here. Other common respiratory viruses are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=see_link\">",
"     \"Parainfluenza viruses in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the Paramyxoviridae family, there are two subfamilies, Pneumovirinae and Paramyxovirinae. Genetic analysis determined that hMPV is most similar to the Pneumovirinae family, of which respiratory syncytial virus is a prominent member.",
"   </p>",
"   <p>",
"    HMPV is an enveloped virus with a nonsegmented negative-sense RNA genome. HMPV is most closely related phylogenetically to avian metapneumovirus (APV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ]. The complete genome sequence reveals a high level of homology with APV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/5\">",
"     5",
"    </a>",
"    ]. Phylogenetic analysis has identified two subgroups of hMPV, subgroups A and B, and two clades within each of these subgroups (designated A1, A2, B1, and B2), which often circulate concurrently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A study of 727 Australian hMPV isolates was undertaken from 2001 to 2004, to determine the epidemiologic profile of genetic subtypes associated with acute respiratory tract infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/7\">",
"     7",
"    </a>",
"    ]. Concurrent annual circulation of all four hMPV subtypes was common, although a single, and usually different, hMPV subtype predominated each year.",
"   </p>",
"   <p>",
"    Given the close relationship between hMPV and APV, it was speculated that hMPV might have originated from birds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ]. Although genetically similar, animal experiments have shown that hMPV is not an avian virus since it does not infect chickens or turkeys. In contrast, inoculation of macaque monkeys with hMPV does lead to significant viral replication restricted to the respiratory tract with the subsequent development of upper respiratory symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral replication has been demonstrated in the respiratory tracts of experimentally infected chimpanzees and monkeys and is associated with mild upper respiratory tract signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/8\">",
"     8",
"    </a>",
"    ]. The integrin alpha-V-beta-1 has been identified as a receptor that facilitates infection of epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/9\">",
"     9",
"    </a>",
"    ]. In a mouse model, viral RNA and significant airway inflammation were prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/10\">",
"     10",
"    </a>",
"    ]. Infection was also associated with mucus hyperproduction and hyperplasia of the respiratory epithelium, with resultant airway obstruction and hyperresponsiveness after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge. These data are consistent with that from studies of other respiratory viruses suggesting that the pathogenesis of severe respiratory infections in childhood may be associated with the development of, or susceptibility to, asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal transmission studies have not been reported, but it is likely that transmission is by direct or close contact with contaminated secretions, which may involve large particle aerosols, droplets, or fomites. Nosocomial infections have been reported in hospitalized children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/12\">",
"     12",
"    </a>",
"    ], including in a pediatric hematology-oncology ward [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/13\">",
"     13",
"    </a>",
"    ], and in hospitalized adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/14\">",
"     14",
"    </a>",
"    ]. Transmission to family members appears to be very efficient when an index case becomes ill, with an estimated five-day interval between the onset of symptoms in an index patient and the onset of symptoms in contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon reports from the Netherlands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ], the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/16\">",
"     16",
"    </a>",
"    ], Finland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/17\">",
"     17",
"    </a>",
"    ], Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/3\">",
"     3",
"    </a>",
"    ], Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/2,4\">",
"     2,4",
"    </a>",
"    ], Kenya [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/18\">",
"     18",
"    </a>",
"    ], China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/19\">",
"     19",
"    </a>",
"    ], and many other countries, the virus is ubiquitous and has been associated with infection for at least 60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1,20\">",
"     1,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HMPV can cause upper and lower respiratory tract infection in patients of all age groups, but symptomatic disease most often occurs in young children or older adults. In a Canadian series of 37 patients, 35 percent occurred in children under the age of five and 46 percent in adults above the age of 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/2\">",
"     2",
"    </a>",
"    ]. Many infected children are under the age of one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HMPV appears to have a seasonal variation: late winter and early spring the United States, the Netherlands, the United Kingdom, Norway, and Finland, and late spring and summer in Hong Kong [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1,12,21,24\">",
"     1,12,21,24",
"    </a>",
"    ]. However, one summer outbreak of respiratory HMPV illnesses was described in 26 residents and 13 staff member in a US-based long-term care facility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seroprevalence data suggest that most children are infected by the age of five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ]. The frequency of hMPV infection in children can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, nasal wash specimens were tested for the presence of hMPV in 463 otherwise healthy infants and children who presented with an acute respiratory illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21\">",
"       21",
"      </a>",
"      ]. Twelve percent of lower respiratory tract illnesses were associated with hMPV infection, while hMPV was also detected in 15 percent of samples from 261 patients with upper respiratory tract infection. The mean age of onset was also similar to RSV (11.6 versus 13.0 months).",
"     </li>",
"     <li>",
"      In a second series, respiratory specimens were obtained from 668 children less than five years of age who had negative test results for RSV, influenza, adenovirus, and parainfluenza viruses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/22\">",
"       22",
"      </a>",
"      ]. Upon subsequent testing with polymerase chain reaction (PCR), the proportion of cases due to hMPV was 8.1 percent overall, and 18 and 25 percent in the peak months of March and April. Sixty percent of the children with hMPV infection were less than one year of age.",
"     </li>",
"     <li>",
"      In a prospective population-based surveillance study in which children less than five years of age who presented with an acute respiratory illness or fever were tested for hMPV using real-time reverse transcriptase PCR, hMPV was detected in 200 of 3490 hospitalized children (6 percent), 222 of 3257 children in outpatient clinics (7 percent), 224 of 3001 children in the emergency department (7 percent), and 10 of 770 asymptomatic controls (1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/23\">",
"       23",
"      </a>",
"      ]. Overall annual rates of hospitalization associated with hMPV infection were 1 per 1000 children less than 5 years of age, 3 per 1000 infants less than 6 months of age, and 2 per 1000 children six to 11 months of age. In a retrospective analysis of 1532 infants and children with upper respiratory infections, hMPV RNA was detected in 5 percent of 2384 specimens; acute otitis media was detected in 50 percent of the patients harboring hMPV RNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar proportion of hMPV infection (4 to 9 percent) has been described in children who required hospitalization for an acute respiratory illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The following distribution of causes was noted in a report of 208 such children in whom the diagnosis was made by real-time PCR and other conventional diagnostic methods: RSV in 57 percent; influenza in 24 percent; and hMPV in 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In children less than three years of age who were hospitalized or presented to a clinic with hMPV infection, factors independently associated with hospitalization included age &lt;6 months and the presence of three or more children in the household [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/29\">",
"     29",
"    </a>",
"    ]. Among children who were hospitalized, factors independently associated with severe disease were female sex, prematurity, and genotype B infection.",
"   </p>",
"   <p>",
"    In another study, the majority of inpatients and outpatients less than five years of age with hMPV infection had no underlying conditions, although premature birth and asthma were more frequent among hospitalized children with hMPV than among those without hMPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/23\">",
"     23",
"    </a>",
"    ]. Children hospitalized with hMPV infection (as compared with those hospitalized without hMPV infection) were older and more likely to receive a diagnosis of pneumonia or asthma, to require supplemental oxygen, and to have a longer stay in the intensive care unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMPV infection in adults has been described less well but its frequency as a cause of an acute respiratory illness appears to be lower than in children. In a report that prospectively evaluated 984 respiratory illnesses in younger and older adults during two winter seasons, hMPV infection was identified in 4.5 percent of 984 respiratory illnesses (defined as at least a fourfold increase in anti-hMPV antibodies or more than a twofold increase in antibody titer plus a positive PCR for hMPV), 4.1 percent of asymptomatic subjects, and, in one season, 11 percent of patients with respiratory infections who required hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lower frequency was noted in a national virologic survey of patients of all ages (more than 70 percent adults) with influenza-like illnesses among sentinel general practices in the winter of 2000 to 2001 in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/16\">",
"     16",
"    </a>",
"    ]. HMPV was identified in 9 of 408 specimens (2.2 percent) negative for influenza or RSV, with a higher frequency (4 of 37 [11 percent]) in adults more than 65 years of age.",
"   </p>",
"   <p>",
"    In a study of 1386 adults hospitalized for acute cardiorespiratory illness (pneumonia, acute bronchitis, acute exacerbations of chronic obstructive pulmonary disease or congestive heart failure, upper respiratory tract illness, viral or influenza syndrome, asthma, or respiratory failure) during four consecutive winters in the United States, hMPV was identified in 8.5 percent (range, 4.4 to 13.2 percent) by reverse-transcriptase polymerase chain reaction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serologic testing, depending on the year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One prospective study evaluated the disease burden of respiratory virus infections among adults in a single Tennessee county. Among 508 individuals &ge;50 years of age requiring hospitalization during the winter with an acute respiratory illness, hMPV was detected in 23 patients (4.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/32\">",
"     32",
"    </a>",
"    ]. Over three years, the average rate of hospitalization for hMPV infection was 9.8 per 10,000 residents, which was similar to the rate for influenza (11.8 per 10,000 residents).",
"   </p>",
"   <p>",
"    In summary, hMPV is a common infection in adults that is often asymptomatic but can result in serious infection that requires hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serosurveys suggest that hMPV is usually associated with mild, self-limited infections in children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/16,21,22,24,30\">",
"     16,21,22,24,30",
"    </a>",
"    ]. The incubation period is not fully defined, but is thought to be three to five days in most cases. The kinetics of virus shedding and the relationship between virus shedding and clinical symptoms are not known with precision because human challenge studies have not been performed with wild-type virus. The typical course of mild disease probably involves an asymptomatic period of several days after inoculation, followed by a week of upper respiratory symptoms, with gradual resolution. The typical peak of virus shedding is likely to be about one week after inoculation, and the peak day of symptoms likely follows within a day or two of peak shedding. In severe disease involving the lower respiratory tract, the typical course appears to involve a brief asymptomatic period after inoculation, followed by a day or two of upper respiratory symptoms, which progress to wheezing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other signs of lower respiratory tract involvement. In many patients, the wheezing lasts for several days; however, individuals with a predisposition to reactive airways disease may exhibit prolonged airway dysfunction, with recurrent mild wheezing and cough for days or even several weeks.",
"   </p>",
"   <p>",
"    Among patients who require hospitalization, clinical manifestations can range from bronchiolitis or asthma exacerbation to severe pneumonia and acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/27,28,30,33,34\">",
"     27,28,30,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have described the clinical manifestations of hMPV infection in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21,22,24,33,35,36\">",
"     21,22,24,33,35,36",
"    </a>",
"    ]. The range and frequency of symptoms and signs was illustrated in three series that included approximately 150 children with hMPV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cough &mdash; 68 to 90 percent",
"     </li>",
"     <li>",
"      Rhinitis &mdash; 44 to 77 percent",
"     </li>",
"     <li>",
"      Fever &mdash; 52 to 86 percent",
"     </li>",
"     <li>",
"      Wheezing &mdash; 51 to 56 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of upper respiratory infection include rhinopharyngitis and laryngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21,24\">",
"     21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical diagnoses that were made among 49 children with lower respiratory tract infection in one of the above reports were bronchiolitis (59 percent), croup (18 percent), exacerbation of asthma (14 percent), and pneumonia (8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association with wheezing and exacerbation of asthma has been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/17,22,24,36\">",
"     17,22,24,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Finnish study, which assessed 132 consecutive admissions for wheezing in children who had not taken corticosteroids in the preceding four weeks, found hMPV by PCR in 10 cases (9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Younger age may be associated with hMPV disease. The prevalence of HMPV was significantly higher in children less than three years of age who were hospitalized for wheezing compared to controls (8.9 versus 1.3 percent); however hMPV did not play a significant role in symptomatic respiratory disease in children older than three years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common reasons for hospitalization in hMPV-infected children are acute bronchiolitis and pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. Disease severity may be increased when there is coinfection with RSV. Among RSV-infected children less than two years of age, coinfection with hMPV has been associated with severe RSV bronchiolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], the need for admission to the intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/40\">",
"     40",
"    </a>",
"    ], and a 10-fold increase in the need for mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/39\">",
"     39",
"    </a>",
"    ]. Other studies however, have not identified a high rate of coinfections in hospitalized subjects, so the clinical significance of finding RSV and hMPV RNA in the same sample is uncertain. It is not known if primary hMPV infection that is severe or early in life predisposes to asthma or to a higher frequency of subsequent wheezing associated respiratory illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30424?source=see_link\">",
"     \"Approach to wheezing in children\"",
"    </a>",
"    .) Immunization of HIV-infected children with pneumococcal vaccine reduces the prevalence of hMPV-associated lower respiratory tract illnesses, suggesting an interaction of bacteria and the virus in severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Encephalitis has been reported rarely in children with upper respiratory tract hMPV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In one report of fatal encephalitis in a 14-month-old boy, reverse-transcriptase polymerase chain reaction (PCR) tests of both brain and lung tissue during the post-mortem were positive for hMPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/42\">",
"     42",
"    </a>",
"    ]. In another report, hMPV was detected by PCR from the cerebrospinal fluid and nasal washings of a 10-year-old girl with severe acute encephalitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/43\">",
"     43",
"    </a>",
"    ]. Magnetic resonance imaging of both patients demonstrated multifocal cortical and subcortical lesions. It is not clear whether hMPV is causative in these cases, since virus replication is thought to be limited to the respiratory tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of hMPV infection in adults are similar to those seen in children. In a review cited above, the following frequency of symptoms was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cough &mdash; 100 percent",
"     </li>",
"     <li>",
"      Nasal congestion &mdash; 85 percent",
"     </li>",
"     <li>",
"      Rhinorrhea &mdash; 75 percent",
"     </li>",
"     <li>",
"      Dyspnea &mdash; 69 percent",
"     </li>",
"     <li>",
"      Hoarseness &mdash; 67 percent",
"     </li>",
"     <li>",
"      Wheezing &mdash; 62 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever occurred in only one patient (4 percent). Dyspnea and wheezing were more common in elderly patients, while hoarseness was more common in young adults.",
"   </p>",
"   <p>",
"    HMPV infection has been associated with acute exacerbation of asthma in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, hMPV has been associated with an outbreak of severe lower respiratory tract infection in 96 residents of a long-term care facility, with an attack rate of 72 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Possible role in COPD exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of hMPV in exacerbations of chronic obstructive pulmonary disease is controversial. One group identified the agent to be associated with exacerbations in about five percent of cases, whereas another series could not identify a single patient with hMPV in this context [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that recurrent infection is common. Since all children become infected in the first years of life, all adult infections represent reinfections. Reinfections appear to be mild, although immunocompromised patients may be at risk of severe disease during reinfection. In a case report, for example, a young child with acute lymphoblastic leukemia developed recurrent infections with distinct hMPV strains during two consecutive winters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigenic drift, the molecular basis underlying many reinfections with influenza, likely occurs to some extent with hMPV, but such drift probably is not necessary for reinfection. An analysis of sequences derived from isolates over a 20-year period suggest that point mutations do occur over time; however, hMPV does not appear to sustain a linear accumulation of drift mutations that result in antigenic drift over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of influenza\", section on 'Antigenic drifts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised hosts appear to acquire infection at the same frequency as immunocompetent individuals. However, hMPV infections may be more severe and the course more prolonged in immunocompromised patients due to poor clearance of virus after infection has been established. The role that hMPV may play in immunocompromised hosts has been evaluated in several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort of 688 patients who underwent bronchoscopy was tested for the presence of a variety of respiratory pathogens, including hMPV, in bronchoalveolar lavage (BAL) and bronchial wash specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/49\">",
"       49",
"      </a>",
"      ]. Seventy-two percent were immunocompromised; the most common condition was lung transplantation. The cohort included 210 patients without acute illness who underwent routine bronchoscopy for surveillance after lung transplantation or follow-up of rejection.",
"      <br/>",
"      <br/>",
"      Six cases of hMPV infection were identified using real-time polymerase chain reaction, four of which occurred in immunocompromised patients. Histopathology of lung tissue showed diffuse alveolar damage, hyaline membranes, and smudge cell formation in all five patients who underwent biopsy. All patients with hMPV presented with fever, cough, dyspnea, and wheezing; no cases were identified in asymptomatic individuals. The rate of detection of hMPV was similar to RSV infection.",
"     </li>",
"     <li>",
"      In a study of 251 episodes of upper and lower respiratory tract infection in patients with hematologic malignancies, 9 percent of episodes were associated with hMPV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/50\">",
"       50",
"      </a>",
"      ]. Sixteen of the 22 episodes occurred in hematopoietic cell transplant recipients; three of nine patients with hMPV-related lower respiratory tract disease died.",
"     </li>",
"     <li>",
"      In a retrospective survey of hematopoietic cell transplant recipients who had bronchoalveolar lavage sampling performed because of respiratory illness, hMPV was isolated from 5 of 163 patients (3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/51\">",
"       51",
"      </a>",
"      ]. Infected patients became symptomatic within 40 days after transplantation. Initial symptoms included fever, cough, nasal congestion, and sore throat; four of five infected patients died.",
"     </li>",
"     <li>",
"      In a small study of 21 patients undergoing hematopoietic cell transplantation, persistent nasopharyngeal hMPV infection was demonstrated in most study participants for several months, although these patients were asymptomatic from a respiratory standpoint [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/52\">",
"       52",
"      </a>",
"      ]. These data suggest impaired clearance, as documented in other immunosuppressed hosts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that hMPV-related infection should be considered a potential cause of respiratory illness in immunocompromised patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serologic data suggests that hMPV has been causing clinical disease for at least 60 years, it was only recognized in 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ]. At least two factors contributed to the delay in identifying this agent: the clinical manifestations are not unique and hMPV grows slowly and inefficiently in culture. Reverse transcriptase (RT)-PCR is the most sensitive method for diagnosis of hMPV infection, but the primers and techniques are not standardized among laboratories. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Reverse transcriptase PCR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of hMPV requires inoculation of nasopharyngeal specimens onto special cell lines that are used in research laboratories and requires the use of trypsin treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21\">",
"     21",
"    </a>",
"    ]. Only about one-half of cultures that are positive for hMPV by reverse transcriptase (RT)-PCR yield cultivable virus by current techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardized viral antigens are needed for serologic surveys. An enzyme-linked immunosorbent assay (ELISA) has been developed using the nucleoprotein (N) as antigen, which has been tested in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/54\">",
"     54",
"    </a>",
"    ]. Serum virus neutralizing antibody tests are also available in some research laboratories.",
"   </p>",
"   <p>",
"    Seropositivity is almost universal by age five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"     1",
"    </a>",
"    ]. A definitive serologic diagnosis requires either seroconversion or at least a fourfold increase in titer on serial samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Reverse transcriptase PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for viral RNA in human respiratory secretions based upon reverse transcriptase (RT)-PCR in both conventional and real-time formats has been developed with a variety of different primers and probes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1,21,22,27,30\">",
"     1,21,22,27,30",
"    </a>",
"    ]. As noted above, RT-PCR is the most sensitive method for diagnosis of hMPV infection, but the primers and techniques are not standardized among laboratories. Currently, RT-PCR is available in research laboratories and a limited number of commercial diagnostic laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Shell vial cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shell vial centrifugation cultures are commonly used for rapid diagnosis, but require sensitive and specific monoclonal antibodies. A mouse monoclonal antibody has been developed designated MAb-8 that targets the hMPV matrix protein and is both broadly reactive with hMPV isolates and nonreactive with other common respiratory viruses, such as RSV and influenza. Three cell lines inoculated with laboratory-passaged virus or clinical specimens demonstrated that virus could be identified as early as one to two days after inoculation, which could offer an advantage over routine culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is supportive and varies with the clinical manifestations. There are no clinical data on the susceptibility of hMPV to antiviral therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    , which has activity against respiratory syncytial virus (RSV), is also active against hMPV in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/56\">",
"     56",
"    </a>",
"    ] and reduces viral replication in experimentally infected mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/57\">",
"     57",
"    </a>",
"    ]. The safety and efficacy of ribavirin in humans with hMPV infection are unknown.",
"   </p>",
"   <p>",
"    The rate of secondary bacterial lung infection or bacteremia in patients with hMPV infection has not been defined, but is thought to be low. As a result, the use of antibiotics is not usually indicated in the treatment of infants hospitalized with hMPV bronchiolitis or pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that transmission of hMPV is by direct or close contact with contaminated secretions. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the diagnosis of hMPV infection is not established definitively in most patients, control measures used for RSV and other acute respiratory illnesses are warranted. These include contact precautions including hand washing in all settings and avoidance of cigarette smoke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15640?source=see_link\">",
"     \"Respiratory syncytial virus infection: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the peak of the hMPV season, which is late winter and early spring in the United States and Europe and late spring and summer in Hong Kong [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1,12,21,24\">",
"     1,12,21,24",
"    </a>",
"    ], a significant proportion of infants and young children hospitalized with respiratory symptoms will be infected with hMPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Control of nosocomial spread depends upon compliance with contact precautions, and is complicated by exposures to other infected patients, staff, or family members and other visitors. Patients with known hMPV infection who require hospitalization should be cared for in single rooms or placed with a cohort of hMPV-infected patients. When feasible, patients with RSV infection should be cared for in a separate area from hMPV-infected patients, since coinfection can occur and may be associated with more severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/38,40\">",
"     38,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"     \"General principles of infection control\", section on 'Contact precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Live and subunit experimental vaccine candidates are in preclinical development, but none is near licensure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33304/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1148992649\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human metapneumovirus is a paramyxovirus that was discovered in 2001, but has been responsible for respiratory tract infections for at least 60 years with a worldwide distribution. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is likely that transmission of hMPV is by direct or close contact with contaminated secretions, not small particle aerosols. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HMPV can cause upper and lower respiratory tract infection in patients of all age groups, but symptomatic disease most often occurs in young children or older adults. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serosurveys suggest that hMPV is usually associated with mild, self-limited infections in children and adults. The incubation period is not fully defined, but is thought to be three to five days in most cases, with a typical duration of illness of approximately one week. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who require hospitalization, clinical manifestations can range from bronchiolitis or asthma exacerbation to severe pneumonia and acute respiratory distress syndrome. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reverse transcriptase (RT)-PCR on nasopharyngeal specimens is the most sensitive method for diagnosis of hMPV infection, but the primers and techniques are not standardized among laboratories. HMPV grows slowly and inefficiently in culture. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is supportive and varies with the clinical manifestations. There are no clinical data on the susceptibility of hMPV to antiviral therapy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       Ribavirin",
"      </a>",
"      , which has activity against respiratory syncytial virus (RSV), is also active against hMPV in vitro and reduces viral replication in experimentally infected mice. The safety and efficacy of ribavirin in humans with hMPV infection is unknown. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/1\">",
"      van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/2\">",
"      Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002; 186:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/3\">",
"      Nissen MD, Siebert DJ, Mackay IM, et al. Evidence of human metapneumovirus in Australian children. Med J Aust 2002; 176:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/4\">",
"      Peret TC, Boivin G, Li Y, et al. Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis 2002; 185:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/5\">",
"      van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology 2002; 295:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/6\">",
"      Boivin G, Mackay I, Sloots TP, et al. Global genetic diversity of human metapneumovirus fusion gene. Emerg Infect Dis 2004; 10:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/7\">",
"      Mackay IM, Bialasiewicz S, Jacob KC, et al. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J Infect Dis 2006; 193:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/8\">",
"      Kuiken T, van den Hoogen BG, van Riel DA, et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 2004; 164:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/9\">",
"      Cseke G, Maginnis MS, Cox RG, et al. Integrin alphavbeta1 promotes infection by human metapneumovirus. Proc Natl Acad Sci U S A 2009; 106:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/10\">",
"      Hamelin ME, Prince GA, Gomez AM, et al. Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice. J Infect Dis 2006; 193:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/11\">",
"      Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J 2003; 22:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/12\">",
"      Peiris JS, Tang WH, Chan KH, et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003; 9:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/13\">",
"      Kim S, Sung H, Im HJ, et al. Molecular epidemiological investigation of a nosocomial outbreak of human metapneumovirus infection in a pediatric hemato-oncology patient population. J Clin Microbiol 2009; 47:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/14\">",
"      Tu CC, Chen LK, Lee YS, et al. An outbreak of human metapneumovirus infection in hospitalized psychiatric adult patients in Taiwan. Scand J Infect Dis 2009; 41:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/15\">",
"      Matsuzaki Y, Itagaki T, Ikeda T, et al. Human metapneumovirus infection among family members. Epidemiol Infect 2013; 141:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/16\">",
"      Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002; 8:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/17\">",
"      Jartti T, van den Hoogen B, Garofalo RP, et al. Metapneumovirus and acute wheezing in children. Lancet 2002; 360:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/18\">",
"      Feikin DR, Njenga MK, Bigogo G, et al. Etiology and Incidence of viral and bacterial acute respiratory illness among older children and adults in rural western Kenya, 2007-2010. PLoS One 2012; 7:e43656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/19\">",
"      Wang Y, Chen Z, Yan YD, et al. Seasonal distribution and epidemiological characteristics of human metapneumovirus infections in pediatric inpatients in Southeast China. Arch Virol 2013; 158:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/20\">",
"      Osterhaus A, Fouchier R. Human metapneumovirus in the community. Lancet 2003; 361:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/21\">",
"      Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/22\">",
"      Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged &lt;5 years. J Infect Dis 2004; 189:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/23\">",
"      Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. N Engl J Med 2013; 368:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/24\">",
"      D&oslash;llner H, Risnes K, Radtke A, Nordb&oslash; SA. Outbreak of human metapneumovirus infection in norwegian children. Pediatr Infect Dis J 2004; 23:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/25\">",
"      Louie JK, Schnurr DP, Pan CY, et al. A summer outbreak of human metapneumovirus infection in a long-term-care facility. J Infect Dis 2007; 196:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/26\">",
"      Williams JV, Wang CK, Yang CF, et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 2006; 193:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/27\">",
"      Boivin G, De Serres G, C&ocirc;t&eacute; S, et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003; 9:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/28\">",
"      Mullins JA, Erdman DD, Weinberg GA, et al. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg Infect Dis 2004; 10:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/29\">",
"      Papenburg J, Hamelin M&Egrave;, Ouhoummane N, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. J Infect Dis 2012; 206:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/30\">",
"      Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003; 187:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/31\">",
"      Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med 2008; 168:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/32\">",
"      Widmer K, Zhu Y, Williams JV, et al. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis 2012; 206:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/33\">",
"      Xepapadaki P, Psarras S, Bossios A, et al. Human Metapneumovirus as a causative agent of acute bronchiolitis in infants. J Clin Virol 2004; 30:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/34\">",
"      Schlapbach LJ, Agyeman P, Hutter D, et al. Human metapneumovirus infection as an emerging pathogen causing acute respiratory distress syndrome. J Infect Dis 2011; 203:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/35\">",
"      Esper F, Boucher D, Weibel C, et al. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics 2003; 111:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/36\">",
"      Wolf DG, Greenberg D, Shemer-Avni Y, et al. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr 2010; 156:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/37\">",
"      Williams JV, Tollefson SJ, Heymann PW, et al. Human metapneumovirus infection in children hospitalized for wheezing. J Allergy Clin Immunol 2005; 115:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/38\">",
"      Greensill J, McNamara PS, Dove W, et al. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Emerg Infect Dis 2003; 9:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/39\">",
"      Semple MG, Cowell A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005; 191:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/40\">",
"      K&ouml;nig B, K&ouml;nig W, Arnold R, et al. Prospective study of human metapneumovirus infection in children less than 3 years of age. J Clin Microbiol 2004; 42:4632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/41\">",
"      Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006; 193:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/42\">",
"      Schildgen O, Glatzel T, Geikowski T, et al. Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis 2005; 11:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/43\">",
"      S&aacute;nchez Fern&aacute;ndez I, Rebollo Polo M, Mu&ntilde;oz-Almagro C, et al. Human Metapneumovirus in the Cerebrospinal Fluid of a Patient With Acute Encephalitis. Arch Neurol 2012; 69:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/44\">",
"      Williams JV, Crowe JE Jr, Enriquez R, et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 2005; 192:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/45\">",
"      Boivin G, De Serres G, Hamelin ME, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis 2007; 44:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/46\">",
"      Vicente D, Montes M, Cilla G, P&eacute;rez-Trallero E. Human metapneumovirus and chronic obstructive pulmonary disease. Emerg Infect Dis 2004; 10:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/47\">",
"      Beckham JD, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 2005; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/48\">",
"      Pelletier G, D&eacute;ry P, Abed Y, Boivin G. Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child. Emerg Infect Dis 2002; 8:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/49\">",
"      Sumino KC, Agapov E, Pierce RA, et al. Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis 2005; 192:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/50\">",
"      Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005; 192:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/51\">",
"      Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006; 144:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/52\">",
"      Debiaggi M, Canducci F, Sampaolo M, et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis 2006; 194:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/53\">",
"      Larcher C, Geltner C, Fischer H, et al. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant 2005; 24:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/54\">",
"      Hamelin ME, Boivin G. Development and validation of an enzyme-linked immunosorbent assay for human metapneumovirus serology based on a recombinant viral protein. Clin Diagn Lab Immunol 2005; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/55\">",
"      Landry ML, Ferguson D, Cohen S, et al. Detection of human metapneumovirus in clinical samples by immunofluorescence staining of shell vial centrifugation cultures prepared from three different cell lines. J Clin Microbiol 2005; 43:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/56\">",
"      Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003; 60:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/57\">",
"      Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006; 50:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/58\">",
"      Buchholz UJ, Nagashima K, Murphy BR, Collins PL. Live vaccines for human metapneumovirus designed by reverse genetics. Expert Rev Vaccines 2006; 5:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33304/abstract/59\">",
"      Cseke G, Wright DW, Tollefson SJ, et al. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol 2007; 81:698.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8311 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33304=[""].join("\n");
var outline_f32_33_33304=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1148992649\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Possible role in COPD exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Viral culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Reverse transcriptase PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Shell vial cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1148992649\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30424?source=related_link\">",
"      Approach to wheezing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_33_33305="Role of anticholinergic therapy in COPD";
var content_f32_33_33305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of anticholinergic therapy in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33305/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33305/contributors\">",
"     Raed A Dweik, MD, FACP, FCCP, FRCP(C), FCCM, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33305/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/33/33305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/33/33305/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/33/33305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic obstructive airway diseases are a group of lung diseases that share the common pathophysiologic property of chronic persistent airflow obstruction. These diseases include chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis, bronchiolitis obliterans, and asthma. By virtue of common usage, however, chronic obstructive pulmonary disease (COPD) has come to refer specifically to chronic bronchitis and emphysema.",
"   </p>",
"   <p>",
"    Primary therapy for COPD is directed at reducing airways resistance. To the extent that bronchial smooth muscle constriction and airway inflammation and mucous plugging contribute to airflow obstruction, bronchodilators (along with smoking cessation) can improve lung function. By comparison, there is currently no effective therapy for the irreversible airflow obstruction that results from airway obliteration, peribronchial and peribronchiolar fibrosis, and loss of elastic recoil.",
"   </p>",
"   <p>",
"    Both anticholinergic agents and beta adrenergic agonists are effective in reversing the reversible part of airway obstruction. However, inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide is preferred over beta-2 agonists by many as the bronchodilator of choice in COPD for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Its minimal cardiac stimulatory effects compared to those of beta agonists",
"     </li>",
"     <li>",
"      Its greater effectiveness than either beta agonist or methylxanthine bronchodilators in most studies of patients with COPD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a manifestation of the importance of anticholinergic medications in the treatment of COPD,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide was the only bronchodilator studied in the landmark Lung Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, combination therapy with both beta-agonist and anticholinergic bronchodilators may be helpful in some patients.",
"   </p>",
"   <p>",
"    It is important to recognize that regular long-term therapy with bronchodilators does not alter the natural history of COPD, as was clearly demonstrated by the outcome of the Lung Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/1\">",
"     1",
"    </a>",
"    ]. Since treatment does not alter the natural history of the disease, no treatment is needed in asymptomatic patients. In symptomatic patients, by comparison, relief of dyspnea and improvement in exercise tolerance and quality of life are the main achievable outcomes of therapy in COPD.",
"   </p>",
"   <p>",
"    This topic will review the role of anticholinergic medications in the treatment of COPD, based upon our current understanding of the pharmacology of these medications and the pathophysiology of COPD. The management of acute exacerbations and the approach to the treatment of COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologically active anticholinergic alkaloids exist in the roots, seeds, and leaves of a variety of belladonna plants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2\">",
"     2",
"    </a>",
"    ]. The most important of these naturally occurring alkaloids are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Atropa belladonna, the deadly nightshade, contains mainly the alkaloid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . The same alkaloid is present in Datura stramonium, known as Jamestown or jimson weed, stinkweed, thorn-apple, and devil's apple. The alkaloid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    (hyoscine) is found chiefly in the shrub Hyoscyamus niger (henbane) and Scopolia carniolica.",
"   </p>",
"   <p>",
"    The use of extracts from these plants for the relief of respiratory symptoms and bronchospasm originated thousands of years ago in India and was introduced into Western medicine by British colonists in the early 19th century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    was then isolated in a pure form by Mein in 1831. In 1867, Bezold and Bloebaum showed that atropine blocked the cardiac effects of vagal stimulation, and five years later Heidenhain found that it prevented salivary secretion produced by stimulation of the chorda tympani. In 1859, it was reported that a severe asthma attack was successfully treated by injecting atropine into the vagus nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoke from the leaves of these plants became the preparation of choice for relief of bronchospasm; inhalational and systemic preparations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    were soon available for the treatment of asthma. With the introduction of ephedrine and epinephrine during the 20th century, the use of atropine and related substances for relief of bronchospasm declined. Anticholinergic therapy has again come to the forefront of bronchospastic therapy with the introduction of the synthetic quaternary derivatives of atropine, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    bromide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY AND PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasympathetic nervous system plays a major role in regulating bronchomotor tone. The bulk of autonomic nerves in the human airways are branches of the vagus nerve, whose efferent preganglionic fibers enter the lung at the hilum and travel along the airways into the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/4\">",
"     4",
"    </a>",
"    ]. A diverse set of stimuli can cause a reflex increase in parasympathetic activity that contributes to bronchoconstriction. Acetylcholine (ACh) is the endogenous neurotransmitter at cholinergic nerve endings, and its actions are mediated through nicotinic and muscarinic cholinergic receptors. The figure outlines the role of nicotinic and muscarinic receptors in cholinergic transmission in the airway (",
"    <a class=\"graphic graphic_figure graphicRef58052 \" href=\"mobipreview.htm?1/51/1855\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nicotinic receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic receptors are located on ganglionic neurons and are activated by ACh released from preganglionic vagal fibers (",
"    <a class=\"graphic graphic_figure graphicRef58052 \" href=\"mobipreview.htm?1/51/1855\">",
"     figure 1",
"    </a>",
"    ). These receptors are stimulated by nicotinic agonists and inhibited by nicotinic antagonists like hexamethonium. They are not significantly affected by currently available anticholinergic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Muscarinic receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscarinic receptors are found primarily on the autonomic effector cells that are innervated by postganglionic parasympathetic nerves. There are at least five subtypes of muscarinic receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/6\">",
"     6",
"    </a>",
"    ]. At least three of these are expressed in the lung (",
"    <a class=\"graphic graphic_table graphicRef79055 \" href=\"mobipreview.htm?36/3/36923\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M1 receptors are present on peribronchial ganglion cells where the preganglionic nerves transmit to the postganglionic nerves",
"     </li>",
"     <li>",
"      M2 receptors are present on the postganglionic nerves",
"     </li>",
"     <li>",
"      M3 receptors are present on smooth muscle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    M1 and M3 receptors mediate the parasympathetic bronchoconstrictive effect of the vagus nerve. Vagal fibers synapse and activate nicotinic and M1 muscarinic receptors in parasympathetic ganglia present in the airway wall. Short postganglionic fibers release ACh, which acts on M3 muscarinic receptors in airway smooth muscle. The submucosal glands are also innervated by parasympathetic neurons and have predominantly M3 receptors.",
"   </p>",
"   <p>",
"    The activation of M1 and M3 receptors by ACh and its analogs stimulates secretion by tracheobronchial glands and causes bronchoconstriction. On the other hand, activation of M2 receptors limits further production of ACh and protects against parasympathetic-mediated bronchoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Based upon this information, an ideal anticholinergic agent would inhibit only the M1 and M3 receptors and spare the M2 receptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    (the prototype of muscarinic receptor antagonists) prevents the effects of ACh by competitively blocking its binding to muscarinic receptors in the CNS, peripheral ganglia, and at neuroeffector sites on smooth muscle, cardiac muscle, and secretory glands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2\">",
"     2",
"    </a>",
"    ]. Atropine inhibits secretions of the nose, mouth, pharynx, and bronchi and thus causes dryness of the mucous membranes of the respiratory tract. This action is especially marked if secretion is excessive and is the basis for the use of atropine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    in preanesthetic medication. This depression of mucous secretion and the inhibition of mucociliary clearance, however, are undesirable side effects of atropine in patients with airway disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    is particularly effective against bronchoconstriction produced by parasympathomimetic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    ; it also partially antagonizes bronchoconstriction induced by histamine and bradykinin. In general, however, muscarinic receptor antagonists cause little blockade of the effects of ACh at nicotinic receptor sites. As a result, extremely high doses of atropine or related drugs are required to produce any degree of blockade of the predominantly nicotinic receptors at the neuromuscular junction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TERTIARY VERSUS QUATERNARY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quaternary ammonium drugs (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    ) are synthetic derivatives of the naturally occurring tertiary ammonium compounds (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef55857 \" href=\"mobipreview.htm?43/42/44718\">",
"     figure 2",
"    </a>",
"    ). Ipratropium bromide is derived by the introduction of an isopropyl group to the N atom of atropine. Other quaternary compounds include oxitropium bromide (which is a derivative of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    formed by the introduction of an ethyl group) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    bromide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The structure of the quaternary ammonium compounds (",
"    <a class=\"graphic graphic_figure graphicRef55857 \" href=\"mobipreview.htm?43/42/44718\">",
"     figure 2",
"    </a>",
"    ) renders them freely soluble in water but insoluble in lipids; it is therefore difficult for these compounds to cross biologic barriers that can be easily crossed by the tertiary ammonium compounds like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . Most of the pharmacologic properties that distinguish quaternary ammonium compounds from atropine are due to this feature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tertiary ammonium compounds are lipid-soluble, easily absorbed, and can cause significant side effects, including tachycardia, dry mouth, flushing of the skin, blurred vision, and mood changes",
"     </li>",
"     <li>",
"      Since compounds with a quaternary ammonium structure are poorly absorbed after oral administration, they cause fewer side effects",
"     </li>",
"     <li>",
"      Quaternary compounds generally exhibit a greater degree of nicotinic blocking activity and consequently are likely to interfere with neuromuscular transmission in doses that more closely approximate those that cause muscarinic block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide is the most widely studied and used quaternary anticholinergic medication in the treatment of COPD. Ipratropium bromide produces effects similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    when each agent is administered parenterally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. These include bronchodilation, tachycardia, and inhibition of salivary secretion. Unlike atropine, however, ipratropium lacks appreciable effect on the CNS, is poorly absorbed from the lungs or the gastrointestinal tract, and does not inhibit mucociliary clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The use of ipratropium in patients with COPD therefore avoids the increased accumulation of lower airway secretions and the antagonism of beta-adrenergic agonist-induced enhancement of mucociliary clearance that is encountered with atropine.",
"   </p>",
"   <p>",
"    Even when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide is administered in amounts many times the recommended dosage, little or no change occurs in heart rate, blood pressure, bladder function, intraocular pressure, or pupillary diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ]. This selectivity results from the very inefficient absorption of the drug from airway or gastrointestinal mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IPRATROPIUM AS A SINGLE AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide (Atrovent) was first introduced to the United States in 1987 in a metered dose inhaler (MDI) form. In addition, a 0.02 percent solution for nebulized administration has also been introduced. Each puff of the MDI provides 18 mcg of ipratropium bromide, and each canister contains 200 inhalations.",
"   </p>",
"   <p>",
"    The propellant in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    MDIs has traditionally been a chlorofluorocarbon (CFC). Following adoption of the Montreal protocol (an international agreement to ban CFCs), ipratropium inhalers that contain hydrofluoroalkane (HFA) have become widely available. Prior to initial use of the HFA formulation, the inhaler should be actuated into the air twice; this step should be repeated if the inhaler is not used for more than three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose from the MDI is 2 puffs 4 times daily, but the medication is well tolerated when given in much higher doses (4 to 8 puffs 4 times a day). Although the dose of the nebulized solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    can be as low as 50 to 125 mcg, the dose may need to be increased for the treatment of acute bronchospasm. Each 2.5 mL unit dose contains 500 mcg of ipratropium, which is the currently recommended dose to be given 3 to 4 times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of bronchodilation produced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    is thought to reflect the level of parasympathetic tone. In normal individuals, the inhalation of ipratropium provides complete protection against bronchoconstriction from inhaled irritants like sulfur dioxide, ozone, nebulized citric acid, or cigarette smoke. However, patients with asthma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atopy are more responsive to these irritants and are less well protected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    also causes marked reduction in airway sensitivity to inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    and a modest reduction in airway sensitivity from challenge with histamine or bradykinin; however, it provides little protection against the bronchoconstriction induced by 5-HT or the leukotrienes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide by MDI achieves its maximal effect in adults in a dose of 40 to 80 mcg, delivered by 2 to 4 actuations of the inhaler [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ], or 50 to 125 mcg delivered by nebulizer. Because penetration of inhaled particles into the airways is impaired when the airways are severely obstructed, higher doses may be needed for a maximal effect in patients with more severe airway disease. Higher doses may result in bronchodilation of greater duration than magnitude. Tachyphylaxis to ipratropium has not been demonstrated, and thus its efficacy is not blunted over years of regular use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    has been shown to alleviate dyspnea, increase exercise tolerance, and improve gas exchange in patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/8\">",
"     8",
"    </a>",
"    ]. Ipratropium, however, does not have anti-inflammatory properties and does not alter the natural history of the disease in terms of lung function or mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Lung Health Study prospectively evaluated the effect of smoking cessation with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    therapy on the decline of lung function in 5,887 male and female smokers with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/1\">",
"     1",
"    </a>",
"    ]. In this landmark study, the anticholinergic bronchodilator ipratropium was chosen as the bronchodilator of choice because of its low frequency of side effects, relatively long duration of action, and demonstrated bronchodilator efficacy in patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/1,7,10\">",
"     1,7,10",
"    </a>",
"    ]. Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The regular use of inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide (2 puffs three times daily from a metered dose inhaler) produced an increase in FEV1 that was evident at the end of the first year and was maintained for the succeeding four years; however, this improvement did not increase with time (",
"      <a class=\"graphic graphic_figure graphicRef56320 \" href=\"mobipreview.htm?27/2/27694\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The improvement in lung function appeared to reverse within a few weeks of stopping the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As concluded by the study investigators, these results reflect the relatively short term, pharmacologically mediated change in lung function attributable to the bronchodilator. Since this effect is presumably available at any time during the course of disease, these results support the use of bronchodilators for symptomatic benefit, including relief of dyspnea and improvement in exercise tolerance. By comparison, no treatment is needed in asymptomatic patients, as therapy does not alter the natural history of the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IPRATROPIUM VERSUS BETA-AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In COPD,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    has been shown to be superior to the beta-adrenergic agonists in both short- and long-term studies. As an example, in a multicenter, randomized trial of 260 patients with COPD but no asthma or atopy, ipratropium was more potent at its peak effect and was longer acting than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/10\">",
"     10",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef73667 \" href=\"mobipreview.htm?21/28/21966\">",
"     figure 4",
"    </a>",
"    ). Similar findings were also reported for nebulized ipratropium bromide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, some studies have shown that ipratropium bromide produced significant bronchodilation in patients who did not respond to inhaled sympathomimetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    therapy may also result in an improvement in the quality of life of patients with COPD. In a multicenter, randomized trial of 223 patients with COPD, the efficacy of nebulized ipratropium (500 mcg) was compared to nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    (2.5 mg) (each taken 3 times daily for up to 83 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/12\">",
"     12",
"    </a>",
"    ]. Although clinical improvement was noted in both groups, the ipratropium bromide group had a greater symptomatic benefit and scored higher on quality of life questionnaires.",
"   </p>",
"   <p>",
"    Although the side effects of inhaled beta-2 agonists are generally minor, they may produce troublesome tremor in the dosages required to produce bronchodilation in COPD. In addition, beta-2 agonist use in patients with COPD may be accompanied by pulmonary vasodilation, which may worsen ventilation-perfusion matching and result in a slight fall in arterial PaO2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/13\">",
"     13",
"    </a>",
"    ]. The beneficial effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide combined with its minimal side effects make this agent the preferred bronchodilator for COPD in the ambulatory setting.",
"   </p>",
"   <p>",
"    Fewer studies are available in acute exacerbations of COPD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several physiologic reasons exist for the potential benefit of combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    and beta agonists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticholinergics act predominantly on the proximal large airways, while sympathomimetics act on the more distal small airways",
"     </li>",
"     <li>",
"      The two classes of medications cause bronchodilation via different mechanisms: beta agonists are thought to cause bronchodilation by directly acting on muscle, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      causes bronchodilation by reducing cholinergic tone",
"     </li>",
"     <li>",
"      Coadministration of adrenergic and anticholinergic agents provides the rapid onset of action of the former and the sustained activity of the latter; the potency of their combined action is utilized at intermediate times",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When recommended doses of bronchodilators are used in COPD, the administration of combinations of agents generally results in more bronchodilation than does the administration of single agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. As an example, one crossover trial of 863 patients found that combination therapy resulted in a significantly higher peak FEV1 that was 24 percent higher than that achieved by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    alone, and 37 percent greater than that achieved with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/15\">",
"     15",
"    </a>",
"    ]. In patients with COPD, this offers a potential therapeutic advantage over nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    alone without a risk of increased side effects.",
"   </p>",
"   <p>",
"    There is little evidence to indicate in which sequence to give the two drugs and whether they should be given in immediate sequence or should be separated by an interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"     7",
"    </a>",
"    ]. Metered dose inhalers containing a fixed combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/51/28469?source=see_link\">",
"     ipratropium-albuterol",
"    </a>",
"    are available in the United States and many other countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TIOTROPIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     Tiotropium",
"    </a>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef55857 \" href=\"mobipreview.htm?43/42/44718\">",
"     figure 2",
"    </a>",
"    ) is a long-acting anticholinergic agent with M1 and M3 selectivity (",
"    <a class=\"graphic graphic_table graphicRef79055 \" href=\"mobipreview.htm?36/3/36923\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In the United States it is administered via a dry powder inhaler (",
"    <a class=\"graphic graphic_picture graphicRef57922 \" href=\"mobipreview.htm?41/43/42675\">",
"     picture 1",
"    </a>",
"    ), while in other countries it is administered via a soft mist inhaler. Although it binds to all three muscarinic receptors, tiotropium comes off the M2 receptor rather rapidly without affecting the inhibition of M1 and M3 receptors. Tiotropium may therefore have a theoretical advantage over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide, since the M2 receptor mediates bronchodilation. Tiotropium is longer acting than ipratropium and may allow a more convenient dosing schedule for patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. One study randomized 288 patients with severe COPD to receive either tiotropium once per day or ipratropium four times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/21\">",
"     21",
"    </a>",
"    ]. Significantly greater bronchodilation was achieved and significantly less",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    was used in the tiotropium group.",
"   </p>",
"   <p>",
"    Continuous therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    appears to be well tolerated, and is associated with decreased dyspnea, improved quality of life, fewer acute exacerbations, a reduction in hyperinflation, and improved overnight arterial oxygen saturation compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]. A meta-analysis of 22 trials with 23,309 participants found that tiotropium therapy resulted in a significantly improved mean quality of life (mean difference [MD] -2.89, 95% CI -3.35 to -2.44) and significantly reduced the number of participants suffering from exacerbations (OR 0.78, 95% CI 0.70 to 0.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/29\">",
"     29",
"    </a>",
"    ]. In this analysis, the number needed to treat to benefit (NNTB) was 16 to prevent one exacerbation. Tiotropium also reduced exacerbations leading to hospitalization but no significant difference was found for hospitalization of any cause or mortality.",
"   </p>",
"   <p>",
"    The lack of an immediate bronchodilator response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    does not correlate with the results of extended therapy. This was demonstrated in a large randomized controlled trial comparing one year of therapy with tiotropium to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/30\">",
"     30",
"    </a>",
"    ]. The presence or absence of a bronchodilator response on the first day of treatment did not predict long-term outcome, and patients treated with tiotropium had improved spirometry and less subjective dyspnea than control patients regardless of the response to the first dose.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     Tiotropium",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    , appears to provide superior bronchodilation and improvements in dyspnea when compared with long-acting beta-agonists in patients with stable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This was demonstrated in a large three-armed trial comparing tiotropium with the long-acting beta-agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    and placebo in over 1200 patients with COPD. Therapy with tiotropium resulted in a significant delay in the time until first exacerbation, and fewer exacerbations per year, than treatment with salmeterol or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the long-term,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    improves lung function and quality of life, and also decreases the risk of exacerbations, but does not reduce the rate of decline in forced expiratory volume in one second (FEV1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/34\">",
"     34",
"    </a>",
"    ]. This was demonstrated in a randomized four year trial, Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT), which compared inhaled tiotropium to placebo. Patients were allowed to take other respiratory medications, as needed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Potential risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A further analysis of the UPLIFT trial found that the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    (relative to placebo) on pre and post bronchodilator FEV1, exacerbation risk, and quality of life was present irrespective of smoking status, although the magnitude of the benefit varied among current smokers, intermittent smokers, and continuing exsmokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1814588\">",
"    <span class=\"h1\">",
"     ACLIDINIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"     Aclidinium",
"    </a>",
"    bromide is a long-acting anticholinergic agent that selectively inhibits the M3 muscarinic receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Aclidinium is longer acting than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    , but shorter acting than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    . It is administered via a dry powder inhaler (Tudorza Pressair) at a dose of 400 mcg twice daily (",
"    <a class=\"graphic graphic_picture graphicRef57922 \" href=\"mobipreview.htm?41/43/42675\">",
"     picture 1",
"    </a>",
"    ). It was initially developed as a once daily medication, but further study showed better efficacy with the twice daily dosing schedule. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Muscarinic receptors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Support for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"     aclidinium",
"    </a>",
"    in stable COPD comes from several trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 24-week trial, subjects with moderate to severe COPD were randomly assigned to twice-daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"       aclidinium",
"      </a>",
"      (200 mcg or 400 mcg) or placebo (",
"      <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/36\">",
"       36",
"      </a>",
"      ]. Significant improvements in trough and peak FEV1 were noted with both doses of aclidinium and peak FEV1 improvements in week 24 were comparable with day one. Health status assessed by questionnaire and dyspnea also improved relative to placebo.",
"     </li>",
"     <li>",
"      In a small trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"       aclidinium",
"      </a>",
"      400 mcg twice daily was compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      18 mcg once daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/40\">",
"       40",
"      </a>",
"      ]. With both medications, improvements in FEV1 were greater than with placebo but not significantly different from each other.",
"     </li>",
"     <li>",
"      In an unpublished trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"       aclidinium",
"      </a>",
"      400 mcg twice daily was compared with the long-acting beta agonist",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      12 mcg twice daily in subjects with moderate-to-severe COPD (GOLD stage II and III) (",
"      <a class=\"graphic graphic_table graphicRef82690 \" href=\"mobipreview.htm?34/28/35275\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/41\">",
"       41",
"      </a>",
"      ]. The trough and peak FEV1 values were not significantly different between these groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger studies with longer treatment durations are needed to provide meaningful comparisons between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"     aclidinium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    , and the long-acting beta agonists.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"     Aclidinium",
"    </a>",
"    is not appropriate for acute relief of dyspnea due to bronchoconstriction and has not been studied in subjects younger than 18.",
"   </p>",
"   <p>",
"    The most common adverse effects (with a frequency greater than placebo) in clinical trials were headache (6.6 versus 5 percent), nasopharyngitis (5.5 versus 3.9 percent), and cough (3 versus 2.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/41\">",
"     41",
"    </a>",
"    ]. Anticholinergic side effects, such as urinary retention, dry mouth, and constipation, were not different from placebo in clinical trials including 2717 patients on twice daily dosing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/36,41\">",
"     36,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional quaternary anticholinergic agents are currently being evaluated for a potential role in the treatment of patients with COPD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxitropium bromide (Ba 253 Br) is an effective anticholinergic bronchodilator that inhibits all 3 muscarinic airway receptors. It may be a more potent bronchodilator than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      at lower doses, but there is no difference in maximal response between the two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Telenzepine is an experimental M1-selective muscarinic receptor antagonist that has been found to improve lung function in patients with nocturnal asthma but not in those with COPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tiquizium is another experimental antimuscarinic agent that inhibits all 3 muscarinic receptor subtypes. It has been shown to be an effective bronchodilator in both animals and humans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POTENTIAL RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"     aclidinium",
"    </a>",
"    from the mouth and gastrointestinal tract is low, although some absorption from the lung does occur. Systemic bioavailability of tiotropium is estimated to be about 20 to 25 percent, while bioavailability of aclidinium is less than 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91301605\">",
"    <span class=\"h2\">",
"     Cardiovascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the minimal impact of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    on heart rate and blood pressure, concern has been raised regarding possible adverse cardiovascular effects in patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/34,48-51\">",
"     34,48-51",
"    </a>",
"    ]. Conflicting findings have been reported in multiple studies and meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/34,48-54\">",
"     34,48-54",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Understanding Potential Long-Term Impacts on Function with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       Tiotropium",
"      </a>",
"      (UPLIFT) trial randomized patients to either tiotropium or placebo in addition to other, unrestricted respiratory medications for four years. A significantly lower rate of cardiac adverse events was found in the tiotropium group (RR 0.84 [95% CI, 0.73 to 0.98]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/34\">",
"       34",
"      </a>",
"      ]. Cardiac mortality was also decreased in the tiotropium group (HR 0.86 [95% CI, 0.75 to 0.99]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of cardiovascular events was further examined using the clinical trial safety database for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      , which monitored 19,545 patients with moderate to severe COPD (including the UPLIFT data), who were randomly assigned to tiotropium or placebo in a total of 30 trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/54\">",
"       54",
"      </a>",
"      ]. No increase in all-cause mortality, cardiovascular mortality, or cardiovascular events was found in the tiotropium group.",
"     </li>",
"     <li>",
"      In a prior meta-analysis of 17 randomized trials enrolling nearly 15,000 patients, but not including the UPLIFT trial, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      for more than 30 days significantly increased the risk of myocardial infarction (RR 1.53 [95% CI, 1.05 to 2.23]) and cardiovascular death (RR 1.80 [95% CI, 1.17 to 2.77]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There remains the possibility that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    have different effects on cardiovascular events. The potential effect of ipratropium on cardiovascular events was examined in a cohort study of 82,717 United States veterans with COPD who were followed from 1999 to 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/53\">",
"     53",
"    </a>",
"    ]. The hazard ratio for cardiovascular events among patients who had four or fewer 30 day prescriptions for ipratropium was 1.40 [95% CI 1.30-1.51], and the hazard ratio among those with more than four 30 day prescriptions was 1.23 [95% CI 1.13-1.36]. The case cohort design results in several limitations on the interpretation of the findings.",
"   </p>",
"   <p>",
"    Further data on the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide is needed from randomized trials in which cardiovascular endpoints are specifically sought and defined. In the meantime, any potential for cardiovascular risk should be balanced against the",
"    <strong>",
"     known",
"    </strong>",
"    benefits of these inhaled anticholinergic agents (eg, reduced frequency of exacerbations, fewer hospitalizations, and improved dyspnea).",
"   </p>",
"   <p>",
"    A meta-analysis of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    versus placebo included a subgroup analysis comparing the tiotropium dry powder (available in the United States) and Respimat soft mist inhaler devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/29\">",
"     29",
"    </a>",
"    ]. With the dry powder inhaler there were fewer deaths in the tiotropium group (Peto OR 0.92, 95% CI 0.80 to 1.05) than in the placebo group (yearly rate 2.8%), but with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than with placebo (yearly rate 1.8%). However, methodologic concerns related to uneven study discontinuation limit the conclusions that can be drawn from this trial. One possible explanation for the observed higher mortality associated with the Respimat device is that higher peak plasma concentrations of tiotropium are achieved with that device than with the dry powder Handihaler.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91301509\">",
"    <span class=\"h2\">",
"     Acute urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic absorption of inhaled anticholinergic agents has the potential to increase the risk of acute urinary retention in susceptible patients such as those with benign prostatic hypertrophy (BPH) or lower urinary tract symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/49,56-58\">",
"     49,56-58",
"    </a>",
"    ]. Studies addressing this concern have yielded conflicting results.",
"   </p>",
"   <p>",
"    Studies suggesting an increased risk of urinary retention include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pooled analysis of 19 randomized trials, the relative risk of symptoms of urinary retention was 10.93 (95% CI, 1.26-94.88) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/49\">",
"       49",
"      </a>",
"      ]. However, the severity of the urinary symptoms was not delineated.",
"     </li>",
"     <li>",
"      A nested case control study of 565,073 older adults with COPD examined the risk of acute urinary retention associated with use of inhaled anticholinergic agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/56\">",
"       56",
"      </a>",
"      ]. Among men with BPH, the likelihood of acute urinary retention was greater in those taking an inhaled anticholinergic agent (OR, 1.81, 95% CI, 1.46-2.24) and further increased among those taking both short and long-acting anticholinergic agents compared with monotherapy (OR, 1.84, 95% CI, 1.25-2.71) or nonusers (2.69, 1.93-3.76).",
"     </li>",
"     <li>",
"      A separate nested case-control study of 22,579 patients with COPD found an increased risk of acute urinary retention among those on inhaled anticholinergic agents (adjusted odds ratio 1.40, 95% CI 0.99-1.98) compared with non-users [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/57\">",
"       57",
"      </a>",
"      ]. The risk associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      did not appear different from that associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, reassuring data comes from these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The UPLIFT trial that randomly assigned approximately 6000 patients with COPD to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      or placebo for four years included patients with BPH whose symptoms were controlled with treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/34\">",
"       34",
"      </a>",
"      ]. Urinary retention occurred more often in the tiotropium group than placebo (rate ratio, 1.65, 95% CI, 0.92-2.93), but the difference was not statistically significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 25 patients with COPD and BPH, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      for months was not associated with any cases of acute urinary retention nor urinary parameters such as maximal flow rate (Q-max), average flow rate (Q-ave), postvoid residual urine volume (PVR), or bladder voiding efficiency (BVE) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/33/33305/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical trials with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"       aclidinium",
"      </a>",
"      have not noted an increased risk of acute urinary retention. (See",
"      <a class=\"local\" href=\"#H1814588\">",
"       'Aclidinium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We are cautious when initiating inhaled anticholinergic therapy in patients with known BPH and advise patients to report any changes in urinary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parasympathetic activity regulates bronchomotor tone via the vagus nerve. Impulses from the vagus nerve lead to secretion of acetylcholine, which in turn acts through nicotinic and muscarinic cholinergic receptors on airway smooth muscle and tracheobronchial submucosal glands. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Physiology and pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The muscarinic receptors M1 and M3 on airway smooth muscle cells mediate the parasympathetic bronchoconstrictive effect of the vagus nerve (",
"      <a class=\"graphic graphic_figure graphicRef58052 \" href=\"mobipreview.htm?1/51/1855\">",
"       figure 1",
"      </a>",
"      ). M2 receptors are located on postganglionic nerves; activation of M2 receptors limits further production of acetylcholine and protects against bronchoconstriction mediated via the parasympathetic nerves. Theoretically, blocking M1 and M3 without M2 would optimize the bronchodilator effect. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Physiology and pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The inhaled anticholinergic medications interrupt vagal-induced bronchoconstriction.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       Ipratropium",
"      </a>",
"      bromide is an inhaled quaternary ammonium that blocks all three muscarinic receptors (M1, M2, M3).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       Tiotropium",
"      </a>",
"      bromide, another quaternary ammonium, predominantly blocks the M1 and M3 receptors (",
"      <a class=\"graphic graphic_table graphicRef79055 \" href=\"mobipreview.htm?36/3/36923\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Physiology and pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In COPD,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      is superior to the beta-adrenergic agonists in both short- and long-term studies of acute bronchodilation and in long-term improvement in dyspnea and quality of life (",
"      <a class=\"graphic graphic_figure graphicRef73667 \" href=\"mobipreview.htm?21/28/21966\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ipratropium as a single agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When used in COPD, the combination or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/51/28469?source=see_link\">",
"       ipratropium-albuterol",
"      </a>",
"      provides greater bronchodilation than either agent used alone. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       Tiotropium",
"      </a>",
"      , a dry powder inhaler, is more long-acting than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      , but does not have an acute bronchodilating effect. Nonetheless, in COPD, it provides superior long-term bronchodilation compared to ipratropium. It also reduces the frequency of exacerbations and hospitalizations, and improves dyspnea when compared with long-acting beta-agonists. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Tiotropium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13764?source=see_link\">",
"       Aclidinium",
"      </a>",
"      , administered by dry powder inhaler, is more long-acting than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      , but shorter acting than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      . At a dose of 400 mcg twice daily, it improves pulmonary function, health status, and dyspnea relative to placebo. (See",
"      <a class=\"local\" href=\"#H1814588\">",
"       'Aclidinium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the minimal impact of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"       tiotropium",
"      </a>",
"      on heart rate and blood pressure, data are conflicting regarding possible adverse cardiovascular effects of these agents in patients with COPD. Based on available data, we believe that the potential for cardiovascular risk is extremely small and should be balanced against the",
"      <strong>",
"       known",
"      </strong>",
"      benefits. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Potential risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Integration of anticholinergic agents into the management of COPD is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"       \"Management of stable chronic obstructive pulmonary disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"       \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/1\">",
"      Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497.",
"     </a>",
"    </li>",
"    <li>",
"     Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th, Hardman JG, Limbird LE, Molinoff PB, et al (Eds), McGraw-Hill, New York 1996. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/3\">",
"      Courty, MA. Treatment of asthma. Edin Med J 1859; 5:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/4\">",
"      Richardson JB. Nerve supply to the lungs. Am Rev Respir Dis 1979; 119:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/5\">",
"      Barnes PJ. Cholinergic control of airway smooth muscle. Am Rev Respir Dis 1987; 136:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/6\">",
"      Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/7\">",
"      Gross NJ. Ipratropium bromide. N Engl J Med 1988; 319:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/8\">",
"      Ziment I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/9\">",
"      Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000; 55:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/10\">",
"      Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med 1986; 81:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/11\">",
"      Chervinsky P. Concomitant bronchodilator therapy and ipratropium bromide. A clinical review. Am J Med 1986; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/12\">",
"      Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am J Med 1996; 100:11S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/13\">",
"      Chapman KR. Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus. Am J Med 1996; 100:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/14\">",
"      In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/15\">",
"      Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/16\">",
"      Gross NJ. Tiotropium bromide. Chest 2004; 126:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/17\">",
"      Tiotropium (Spiriva) for COPD. In: The Medical Letter on Drugs and Therapeutics. The Medical Letter, Inc., New Rochelle, NY 2004; 46:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/18\">",
"      Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994; 150:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/19\">",
"      Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/20\">",
"      Casaburi R, Briggs DD Jr, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/21\">",
"      van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/22\">",
"      Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/23\">",
"      Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD002876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/24\">",
"      Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/25\">",
"      Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/26\">",
"      Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/27\">",
"      O'Donnell DE, Fl&uuml;ge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/28\">",
"      McNicholas WT, Calverley PM, Lee A, et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/29\">",
"      Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7:CD009285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/30\">",
"      Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/31\">",
"      Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/32\">",
"      Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/33\">",
"      Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/34\">",
"      Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/35\">",
"      Tashkin DP, Celli B, Kesten S, et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010; 35:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/36\">",
"      Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/37\">",
"      Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/38\">",
"      de la Motte S, Beier J, Schmid K, et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 2012; 50:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/39\">",
"      Aclidinium Bromide (Tudorza Pressair) for COPD. Med Lett Drugs Ther 2012; 54:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/40\">",
"      Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 &mu;g twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012; 141:745.",
"     </a>",
"    </li>",
"    <li>",
"     Forest Research Institute FDA Advisory committee briefing document. Aclindinium bromide in chronic obstructive pulmonary disease NDA 02450. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM292624.pdf (Accessed July 24, 2012). p.50",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/42\">",
"      Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease. Thorax 1995; 50:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/43\">",
"      Cazzola M, D'Amato G, Guidetti E, et al. An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. Pulm Pharmacol 1990; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/44\">",
"      Ukena D, Wehinger C, Engelst&auml;tter R, et al. The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients. Eur Respir J 1993; 6:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/45\">",
"      Shioya T, Kagaya M, Sano M, et al. Antimuscarinic effect of tiquizium bromide in vitro and in vivo. Eur J Clin Pharmacol 1996; 50:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/46\">",
"      Keam SJ, Keating GM. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/47\">",
"      Ortiz S, Flach S, Caracta C, et al. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol 2012; 52:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/48\">",
"      Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/49\">",
"      Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/50\">",
"      Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/51\">",
"      Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/52\">",
"      Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009; 103:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/53\">",
"      Ogale SS, Lee TA, Au DH, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010; 137:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/54\">",
"      Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/55\">",
"      Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/56\">",
"      Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011; 171:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/57\">",
"      Afonso AS, Verhamme KM, Stricker BH, et al. Inhaled anticholinergic drugs and risk of acute urinary retention. BJU Int 2011; 107:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/58\">",
"      Vande Griend JP, Linnebur SA. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia. Ann Pharmacother 2012; 46:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/59\">",
"      O'Connor AB. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009; 360:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/33/33305/abstract/60\">",
"      Miyazaki H, Suda T, Otsuka A, et al. Tiotropium does not affect lower urinary tract functions in COPD patients with benign prostatic hyperplasia. Pulm Pharmacol Ther 2008; 21:879.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1450 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-84049B631E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33305=[""].join("\n");
var outline_f32_33_33305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSIOLOGY AND PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nicotinic receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Muscarinic receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TERTIARY VERSUS QUATERNARY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IPRATROPIUM AS A SINGLE AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IPRATROPIUM VERSUS BETA-AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TIOTROPIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1814588\">",
"      ACLIDINIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POTENTIAL RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91301605\">",
"      Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91301509\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1450|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/51/1855\" title=\"figure 1\">",
"      Role of nicotinic muscarinic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/42/44718\" title=\"figure 2\">",
"      Anticholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/2/27694\" title=\"figure 3\">",
"      Lung function smokers with COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/28/21966\" title=\"figure 4\">",
"      Ipratropium vs metaproterenol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1450|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/43/42675\" title=\"picture 1\">",
"      Dry powder inhalers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1450|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/3/36923\" title=\"table 1\">",
"      Muscarinic receptors in lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/28/35275\" title=\"table 2\">",
"      Severity of airflow limitation in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_33_33306="Advanced case 14";
var content_f32_33_33306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1053px;\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Advanced case 14",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33306=[""].join("\n");
var outline_f32_33_33306=null;
var title_f32_33_33307="Toxicity comparison for bisphosphonates versus denosumab";
var content_f32_33_33307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxicity comparison for bisphosphonates versus denosumab",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Denosumab",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bisphosphonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Route of administration",
"       </td>",
"       <td class=\"centered\">",
"        Subcutaneous",
"       </td>",
"       <td class=\"centered\">",
"        Intravenous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osteonecrosis of the jaw",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypocalcemia",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotoxicity",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal elimination/need for dose adjustment in renal insufficiency",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flu-like symptoms (acute-phase reaction)",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone, joint, muscle pain",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33307=[""].join("\n");
var outline_f32_33_33307=null;
var title_f32_33_33308="Revised internat criteria SS";
var content_f32_33_33308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised international classification criteria for Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        I. Ocular symptoms: a positive response to at least one of the following questions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Have you had daily, persistent, troublesome dry eyes for more than 3 months?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Do you have a recurrent sensation of sand or gravel in the eyes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Do you use tear substitutes more than 3 times a day?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        II. Oral symptoms: a positive response to at least one of the following questions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Have you had a daily feeling of dry mouth for more than 3 months?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Have you had recurrently or persistently swollen salivary glands as an adult?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Do you frequently drink liquids to aid in swallowing dry food?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        III. Ocular signs-that is, objective evidence of ocular involvement defined as a positive result for at least one of the following two tests:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Schirmer's test, performed without anaesthesia (&le;5 mm in 5 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Rose bengal score or other ocular dye score (&ge;4 according to van Bijsterveld's scoring system)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score &ge;1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 square mm of glandular tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at least one of the following diagnostic tests:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Unstimulated whole salivary flow (&le;1.5 ml in 15 min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive pattern), without evidence of obstruction in the major ducts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        VI. Autoantibodies: presence in the serum of the following autoantibodies:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Antibodies to Ro(SSA) or La(SSB) antigens, or both",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vitali, C, Bombardieri, S, Jonsson, R, et al. Classification criteria for Sj&ouml;gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:664-558. Copyright &copy;2002 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33308=[""].join("\n");
var outline_f32_33_33308=null;
var title_f32_33_33309="Contents: Emergency med calculators";
var content_f32_33_33309=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Emergency med calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Emergency med calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/34/34337\">",
"           Calculator: Adult burn injury fluid resuscitation (Parkland crystalloid estimate)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/29/11730\">",
"           Calculator: Blood ethanol concentration estimation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/26/18849\">",
"           Calculator: Endotracheal tube size for children (Age 1 to 8 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/41/2706\">",
"           Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8DF6F8F8B0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_33_33309=[""].join("\n");
var outline_f32_33_33309=null;
var title_f32_33_33310="Coronary flow abnormalities with myocardial bridging";
var content_f32_33_33310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary flow abnormalities with myocardial bridging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 473px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The contrasting patterns of variation in vessel area (VA) and coronary flow velocity (CFV) in a normal vessel (N) and in a muscle bridge segment (B). The end of the QRS (black line) represents the start of isometric contraction of the left ventricle and point of opening of aortic valve and the end of the T-wave (red line) represents the end of systole and the point of closure of aortic valve. In the bridged segment, vessel area falls markedly during systole and increases during diastole with a marked early peak in diastolic coronary flow velocity (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ge J, Erbel R, Rupprecht HJ, et al. Circulation 1994; 89:1725.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33310=[""].join("\n");
var outline_f32_33_33310=null;
var title_f32_33_33311="Gram stain sputum 7A answer";
var content_f32_33_33311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neisseria meningitidis in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAW4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDQtWt8xxblLS7inPLAYJxz2yP0rSjQ72PzbTgYyeMccf57Vl29wUABD5PbbxwcfT8/8a04nJX5k7Zr86lc+lcSxHGrHBUsOoLDFGpNbQW4kvNqwg/MzDgU+Byy5KsB2zWZ4p0+XU7RIoZ1RA2WVhncKzSTklJ2QU43mky1cXdnaWou3lXyMA5Az2/+sKvWdxFe2yyQtvjPOQcf/XrzpoZLgz2l5ObaBGAQHoceldXYXX2e1iSBlbYMHHcU6tFQSs7v9DsrYTljdG3cKMEY59+ajhJDZP0FZt5rKQwGWRgkfQknpWbceJYbYuSfMKrvAUdRURpTlsjnjh5s6d3B4U9+RjNBXPXOOvU1k6HrdrqasU4ZTggjpWvvQEsDlR3FRKLi+WSszOVNwdmRPvBkbnbgnGck8cUk0LOvB6d/b/GrLLuU4OOnT/Ck2lUPXp3pXEmVGXO1eTk/eH8PB9x+nr+NRGFdzBkx/snn86lO5XIP8XSrOFY7sqM8dM+tO5V2ipbuk0ZaFlZQduUOVDDscdCP/wBdTkAkDaMHg9+Kk8pBJvESbzj5sDPT1qOVDvBVtpx3GQeaV1cVweIMx2jJxgFvw/L8Ky721YybgSVra3qpCnr1prsCmFGT1zjpQpNFwk0YsMbKoDDJFTlW2MFAbg4H8vpU1zJGrNyAQefyqNbiPgBufandvU1d3qAChxuYZPbvj/JqGW3TGRnHsKtgK6jIHTrQVCgKMED0ovYnmsc/qsQaBlOCmew7/WrekW6w2xdcksPTNN1sfJuQdTyKNHeQxHzEKqOhrZtukdDbdI041AiGcMAc5OMdePxH9KkSIF/daahyhCgDkkD8c1KxkCnyym8jhmz+HFYHJqWIYk+8ASSB3OKlC5Ynkgeozk9yKZC244yAQM9amIIXCqHUngD9TUMhjYF3Rqxfcdo560yZG3AK3tjH+fSrG05GeOO3+etNK5Y8spGe/J7VN9QTsRW8Z2lJGbgnp15JOP1FRyRbz86Op656/wD6quKoVQoCCMfdAJ/ljtx3Of5sk/2gCO5zSuCeuhktGW2knLH1PtVaeLJUBQyHrub/AD/Or8jYkbHQ8/Sq8hJ6gitE2dEWZjxAuHIwR39frTHiQuXPRfX+ft+HqauSxLGmclQTk5NV8EkjI4/lW6lc0WpFB8gC8hc4z2A9vbj9fpU5IIxKF3dBhs+3+FRAEDt0/CozL1GT9Kpq7K5bjZ1jzg/XgVUSDeC6kFjyDngcVaAAUnOT1qPzMybVUjjrWkW1sWkQtGVQ4TO3nBPX15qtLbq0eMA9yMfritFlbb93g981E0YPXk+lXGbRSMeS3BULtRlUAAbOv+c9Ky76xt3wPLj2hum0c8YrpLiIYBwD/WqE0IPIPT1rrpVWtbjsmc4dIsim1bWPI7smcdevf1rNubKzlndTZxL5YABbC5zk9q6sRYHb8qytXiuhIGtIiwPUj6V30a8nKzf4kujC234HocG/5TjOfTp2rStmVcA9B07f15rK87ySAxIPYGrkU6uFwwI9q8GSOGUWzYDjHz8jrxVDW7kRWcphdY5tuUYruGevIyMj1HH1qzHIBEehU/zrC1qJZ7KZfOaIkZDj+Hms4JOSuFCCctTyPXL+/wBQmmcy4KMcoOK1PAutXMV6sFxKTCeBnsc07UtK+0PJcRsjmLkspHzD1rFBjt75SpIXIINfVWp1qLppf8A9f2DjNTb02PU9RSKeHyZcgPyGXvWRc7otQtnhRWVBtYN2HardtfxpbrKzBosZJPasu+1fTHLMHG8dxnmvFo05p8tm0aRpOLaZ0drcQwEtHGIwTubHetW21FXZW+8leYr4njhucKrSR4xXW6HffbIBNa8r/EAKjEYOVNc0kc9WjGV2nc7q3uQ6jBPPtS3EzfdjAZh61j2t6YQSVFOj1aKUlZCEcetedyPsefKg73SNWRicb0OO/fNQPO0B+ZcqfXnFNtps7jG2Qe9TKocN5gLZ9Tx/9altuZ2toyaJw6Eo4PTOBmnyYCgtjJ7VmraPbTNJAcKP4fWrMN0s3yvlWA6dOaXoEodYjtzsD8pzSHf5XJ78e3NLE+5dykbew71I6gLuzz796GF7aGBfGRZn4BGcCqsWTKdoxXQT2oYbhyfrVIWLhyVOc1rGatY2VTQdaSP04BHJJ4q2QMhgDz+GOBRHaBIxwcgdjjNOuJkjXaQMY4x2rOTXQyvzPQz5ovPu9jHK1bkiCHC9Dxnr+dPtIsqXYg+pqWRTtPYD061LfQqUuhBEuPmPfOeKsBc8HkZ9Kgfcg+VHcY524P8A9c1ctwCgJzhhnihmbYRRYYkc/h0qSSVo1LMM9zkcnvQN2WxjOafgScMNxHfGeKhsn1K5ucE7vToBz+FIZlzyN2ORnmh4gcj09KrNEd2ccn9PpT0LsjSQgxgevFK6gpuyDn+GoI0KAbhz65qfaB7EHJ9KhojYoyW75yOmOlQmEA5bB7YNazIoXhjg8VVZFU/LndnueKakUpMy54Ny4Kgr02n+tVZoyvGOO2K3JolfrnpziqM1puHBIP8A9atYzNYVEY8uf6k1XOMEgg81rfYkVCXZiR1yax9euIdLtBNNG+wkLkCuim+eSjHc6YNS0Qm2T+Bhg9yM4pfnXAYKW9V/T9KzH1+zjmEX7zgqAdvrXSizBAZn4xnOO2K1qKVO3OrXKn7m5URW25PT0prQuQMYwOp7VesDb3iSfZ5N4jbDcdDVw2mRjb+dYOdnZmLq2OflUY9D6YrnfEd+2nWwkEJdy20KK7e5se6KCeBk9uaozaarjD/MOvIrooVoxknJXRcaqtoc3Awe0ikkXa7KDip47VpcsTkHtitIWKqxznI9az5NPljvZJUuSI3HC+hroVVSvZ2LdRPqdaIEc/dBPoV4xzViO2ReVUY7gjp/n+tRwZDdVwoII9Mnj9KthCow3IzXCzzOZiNGEQjvXJ67FfJPH5OGtiMSLXWyAnkE9ajlhSU4fG71ohPkd9zWjU5Hc4G9so7bTrme0j+fyznr6V5ruMpZnPHpXvF3YFkeMKuxgQR6153rPgicXDPakLETkLzkV7GXY2nG6qOzZ6Ln7aKt9xy0OpSrYtbsztGTxg1VkJZGLLgj17it6PwpqBnKugCYwD6U648N6rHIm+MOmcfKOteosRQT92SL5ak42l6GFAryQk20e9umBzXovgSyuYLdmlQq0mDgCqnhDwpeRXJmuECjJwoPT616XpenG3OWwWx6dK8jM8fGSdKGpnKcaUNXrbYypLadnG5WGfQVhanF5UpJJr0N7fcpU5yfasPUtCN0CUYbq8mjWUZa7GNHEq/vGBpmoMi7SxwD07V1Fhdx3ESB2xXNT6ZNawOrxB1cZV1/nTLGWWAAFsYGPatKkI1FzRNqlOFRXidoqEggHAqrc246N8vPyuOop+nXqSgQsQH7Zq3InmEdCork1T1PPd4PUowusKKkjDJ/I+9WYiGGOpqHULCK6hAJwR0NZSXc1lKUul3IBjeB1qlHm23LUFNabnRxpuHU98f5/CleHAOOSvYVl2+qKx4bKngcVdW6kuDiGMgnvUOLRk4SW46eRYYs55x0NczqOl3V/fW1ylzJAkZ+aNejV0wswBulILerdKyL97+PUrZLWNDEWzIxHQdq0pNp3i9TWk0tEalsoChSOCMcGnSISpAyPX1zUkGEQNjr7UpIOef0rIyb1KcSsi5JLcnJNWLc5QADac+vf/OahPQ8cjmoISxkwc5NO1x2uaq7WAYj5h6VGwweefc96sxAeWpYdutVLoFmwD74qCFuRpcHgAAnParER3AbuCOmazYd6O29TycA+n0q8vAGDkmm0VJFoBMEHk/UnvmkkGOVAPTqcVCGZegNSE5Ocnj14qCLCbyEIIznpVKRmWXg8ccCrwyCOhGKrTkLu2gEjp2poqLGNIzHnOCOSKlTgfNzVUsST06VLEc8envVWG0OkVdoPX6CqOq2EWoWUlvMPkcYzgcVo5AUbulMZldSVI2jjr3pptO6HGTi7o5+y0S1t7SOAxpL5ZyHdQTntWgUIBHGOnI6ijUJ4rSIzysFjA5NYV34lgKhbaCSZ2G4YXqK3jGrWd1qbqM6upt2lvBbKy20ax7zlivc1eTI42n1qjYkvEkpQqHAbae2RV1Cdo7qehFZO99TCatoNmBZcEdT3qnKmCQq8nvVuQnb0Uj3NV2IJbtk5PNUhIzJVC4YnLY61Qvot+AJjA4/iXBJHpyD7Vo3TAMxJXZjjjHPfn8qx7ibE2cHp6/59K6aV27o3jFtHQ24PmFMLjOMkn37dv8A61aIyODwO1UYSIjiXn09QPSr8RD4KkGspM5miO+V1VTFgkjvRjeuXGCBzzVoEnA4/GkkRmYc/KOvHBqBJlbd8/t2PWopN5OAuVHcirrxKMevbtVaeKQqMkjHtRZMpSsRhgTghQD2qaOGKRwNg9jiswhxLgsQc9MVqWUmRhv1FEoJalOpJbMuRRBeFGB1qaEcAyYBycDOcimQyqzkLIjMvUd6kUNvJPPoeOaiyOebk9ycAk5GCMdhTJF6cnP1pVYqcDrxmpEHBJGT60WIu0QPGJF2v16VRn0i3njAdNrdcg9K1Nu0cn8xQu0nJxj6UlpsaRqSWxzc+nyWshYIWQD7+enpTI9SeAEMPkPBJro70KkRA9OmM1yN+FRnZFye69jWkPf3OmFXnVpF9b9HT5WyT74p9xbpcW7I2SxHFYVoiTOXiJSQdUPUVuWSMSBOCp6dOtOceXYbXK7oyoIzY/Kygtu7jrXTafMksWeMDg9sVW1Cx8yMnGSOlY1tcTWNyVbeUPqal/vNepo17aPmdbKoMbAnKn07GoWVSVOOR0qva3C3IVlcEdxVsDOQTkjqaz9TlcXEiByuMAqO/ekKjccgYPqetK6hMZYUBcksMYFAFeNZ2umLBfIz8uBU8aqXJQg08Arlh260mcZcfKD+AoeoN3J1jwwHXJ71HdJtBIxnqSafCSsgJ9ap6mTlmQk0luJLUiYksegqaMbV3YGBWPHK+TljnJ/GtOBjtUNzVOLRo0XIAGQc/Keae0I7kYpsRAAwCB6HtSmT5SOduPzrPUhkL7QRsPI61VklwpLcCpnOcqBmqshbeCBmrSGiVEHVu/FMMMyah58Vx+4MZSSDy/4uxz60kZA7kGklcumAxBz1pjSZKxzwCMHoOtOVP3ePTnGMVymnR6mmuXM9w7rbZwke7II9a6Pziy47Vc4cjte5pOHLsxlzbw3ERjmUMjdQaZb2lrbwgQoq7R8vHanOcdTk9hRg8HJ296m7ta5SbStcGkA5AGc1Ir/Jk8H2NKqIF68+9RSuqZyRge/ekTa42WRBhCwDt0GMZAH/AOqqkkqRMy55NV7/AFKOFCXkUDHrXIXGvJNclUYjGQpJ6110cNOrqlodVHCylqdDqd/FEuWcBfeududRiaT5RuFULmVpsrK7Mc9xwKs2On+aWyQRjqK9GnQhSjeR3KhGnHU9FNzF5aoeQewqEySqyvCDtzyuOKsRAOQAvB6ZGOK0EXCgYHt2rynZHhqaiQ287SbCEIz/AA4xj/OKu5eVThQMdz/MVEUVzy2D2oDPC43AGP8AUVFuxm3fYd5IUbmO49RTZzujKqcEd/WpUdZFJGDxn6UOitxuOeD9RSJv3Md4mDDIP1q/bw5ALg5IqxJGpGQOcdD6U6NQp+XPPrTchuVzmofD19ZeJBd2V2BZy5aVGbJ+grsI/ugP97FIFJOcZJpUUhueh9+KJzlOzl0FOq57kjYA3YGDTiUVeQcdaYd5/MdqjlmCE+3Oc1CM0rkudwOcH1FACgkjrVATkSZyFU/rT/MAX5T8x96dh2Fv8PGT7da5qSJjMc8kn8q6dl8xBnkCq4tVDHp704y5TSErGJHoxZxKh2N1zXQQxpHEvmKGZasQJsHOMdcUTruO5ePYVMpOW5bqOWjIJGO0lRmMfw+lZN/bw3qHnDDgnPOa2I0wx5JBNZ+oW7LL5sQOT1ANTHR6GlOVmcsGm0/+NsA8Ecc1u6XriSoY5yFbs3r7VTu4/tIdm+VsYwRxWIIZI5CpTvkc4rq5Y1V7256ChGqve3Otv7uJIQ8rfu+uR0q5aTpJCDGQY2Ga4+K4mRfLkGYzwc8jFallq0SgREbMDGccVlKk0tNTGph7LQ6F9wDNkLt+Y+47j8qmkwuMAt/DgVm2l08m8u8bKT8oUYwPer1srbdoOUHRTyR9D6VizilFxepLnbzj2ps0AkXnv0xzU8YGDvbJyegxgZOBj6Y/+tQpBYDgZxnBpE3MifS0midZQSj/ACnDEEg+45H1qW1t1t0WMtI4X+KRtzH6mtO6OI8qATWBc3DeYcnaBVJtqxUbyNAv1x9OKj3nHX261nLcAnH3gvQ0rz5B5+lPlHystl9voMimqQW9cj0qsHwC3H40ocb946nrTsPlJSVVskDkVA8gySP8aZPJkAcYHfOMVVmYg5zxTSKUbkquS2B0q0Tn6/Wsh51jIJcD60yTWIol5kzx2rT2cpfCjaNGUnoa+PnD859aZM+CCWAA9TXLXXiOTIEKKFJxuJrJvtUnlb5ZCRnFbwwVST10OyGCk9ztby/EUZbIGOnNYF/r7BGEPyjrntWMNThkiZLkuHVflOT1rFln3g7iSPWuyhgUn7yOulhIx+IfqGoTXRcSOTxxUVlbNLMjSLgLz/8ArpsxDH5RtPvWjpsDS/PK4XjAAPLV6UmqcNNDolFIVVVpyqEsMd/XvW7aIsKdevUEZqrZ2KwsZC+SR09BUsX2k3MwaNfLH3CO4rhqyU9EzkrST0O8QnzEOMKMjr3/AM+lWoecsGJB/KqsBDRjurE8irSkYyMbRXktHzrJshR75qGSfDgE5H1pZFyFI4/WqUuVzjk9O1CRKVy1G4BbBwPSrSEY3FsdwKyCXIwucEHkHpVy3dmCrk4AyOaTQ3EuNJj3A9qDICVyO+emenQ1A+Rnv7io45lDHHXH51LQlE0jOMhlPTjg0LdBQF4yfeqiknOAOeCPWnBCfvEZPTtSsTZdS9KwI3Kfw61SKnIYtuXHNSxr8pJP17c05cAEEAjmi1gTsULoqAenr1qOGYkgAZI7Ut6uNxJP4VVhLYXaOnvVpaGq1RtRS5UZ4qQ5cgAcD1qlbsSccg+tWA5Jxjj+YqGiLE/mYY5/KkJLoy889SOtRI+cDk9cChAXQ54Q9qloaLEW1FIIJ461DLHj5sEj0qXZtB6gmkI6DP4mpsClrcozWqyjcoAI9B2rOvbTzF4TBUdcVsyJIJkCOBEBkjvmmyxGRCM8gdc1V7anRTquJyjwttKvn64FUZ4tql4yd38q6CZPKYmc4AH3gKy1aG9idoBkAkZ6VvCb36HoQqX1M6w1CS2lHmAsO4z06Y/z7V1ltfmUJLEzEZwV9c1xlwhDHuT+lW9J1B0uIoXCFQ2QCMkHBGR+Z/Ota1JTXNEqrRU1dHoEU6H72enrT4poGcsjDPQ461jW+ox+ZsLkEno3U/56VekWOZRgqG74rgcbbnmyp23L07hlBz1681iXaKwPck4pJJJ4N/mNvjz0Haqf2yN8YyTnGMd6qMWKMGtUQrEYnJDYHpQXAY5HA75qSRsjIP41XkPIya133NU7j2mOOCeOeab9q2557Z9KglO0cnp71n3E/PJGPatI0+Y1jC5fub5EjO5gM+pxWRcaxFHkFycdhVDV50EDFyd2OK5g3kgidFwNx6+1ehh8GpK53UaEbXZr3usmXcf4DwBmsv7exbOTs9AaocnqcqKdMVWPKLgnpivUhQhDRI7I2S0NOOR5lbgbR0706JjbsS6GTI7npUGnh1K7cDd1Zj/KpL9hFOGOBCeAPU1DXvcpumrXK8scrgv5bDByT7UzzN3ynBXselacEjspZ1XkHA6ZqqbQLtdxlf7hGaamtmF2QbAVbkM2cBa67SrSL7JCwVWbbycdDWNYWRnkDiLOehNdlbwrFCiEKQBzjjFcOMrWSijlxNWysil5IJz94emOM0kkgjAHQ+i8mrF24GAgBYnA9qYrRwsMruZlySRz/n/CuNNtXOGUrK7Oktd6EYiCxkZLZA5z6frVtSeDxzVCFtp6jHqTVlHB78jnNc7PHaLTtkYYg5OKYysUJVRkjjJ70hkHOeB0p24E49fWkRYQxL1PGe1SImBwBTSyhenFPMhACkZwKkNRec/MOD61Xa3WR23gg57HpxTmlO/BI6dTTxyvqScZpbFK6HRRNHwGJHqx6U4Fieeg9+lSr90AEYFIvyn+E4pEXuS5XYB1A5p2doOACKj34/h5HenLMh44z6CnYhlC8beDkcjtUUA+VSR7AVamAIOFz9KZFtUdOv1q+honoShwOF69iKVJSxxjnPSnLGC/BAApvHIA5JqNAJMttIVuQOM84/DNLEzk/N0PA96ZHjAz19KmcfKNoxnj/wCvUsZKpG0b85Jx1pjkgDntgkUjI/YjH6iobiRkZgVI4xx9agqMbslQKs+5mbJHZv8AIp+9fm6g4rjbfxSg1G4iuiI4UbCtg8mt038e0NuAXHBOK0nTlD4kbzw047ly4hSdSGAIrIvLGSEh4cGMc4HUVftb6N2UBwSB2/nV9lBAIxj+dQm4sSlKnucfcIrPu8sP6isK6EEFyJ1yYwc8NjBrttStI5WxGSk55BIxu68D34rk9V064gk3SodnUkDiuvDzV7Nno4erGWhopHHeWStAWjyQQzckeoq1ak28ZAfLYzz6/WsbT9USBfJlTag9K1DIJBmI7gecipnGUXZ7E1INb7E39pFxtZSpxnBqKZFlwwPzeorL1W4MFnLMiGVk52L1qXS7hngjcqQHUHDdRR7O0edEOnZXRM88qLhkOB3FVJ78IoIBzWq3zDJPWuZ8SXzWHlFYFeNz8znotaUIqpLlS1CmlJ7Cy6r82G5A9O1ZV1fwrMHkkOBztqG6vWlGIcAHuB1rOQpu/fD8SK9Slh4rVo7o0kh+oXou5Ac4XoBVZHiG4S7iQOAPWkumQsREAE9RTI1JUjcceg712xilGyOiKHI0Yjyxyeu30prFEKPCF2n74br+FLIksaKyqGz6DmoZS6x+ZsKkc5I61SVyrl1J4ZZPNMYIjG3hsVBhEcCSYNFuJ9cGobWb92PKTDk5YY/WrsWnxyRneCd56ehqXaG5SfMro0bRQ2GwWjAH5VNFE0t2wL/u/wC6egpLex2W6IzMAOwNNgyuoPbBZAAu7f8AwmuNtO9mKc0bsbxw87hn0p51BQu0OB61ntCHjYMSG9aLayYoNx3bjjpzXI4Q3kzmko7sqalqc7X8MVs0bAnPPeumZQFUSEKcdT3qrDo1t5kcpRTInKselaM4KgBNn/AgTWVWpCXLGC2OSvNPSJftpNzbSc9+mMDsKm3MMsTkVWhcfj0IP8v1qdQrH7oyDkGsbHlEkcpwrEnkDGeKsK+0jnrnpVdRlQXB6jvin/Lyc+2M1LRLJ9wznBwe9P3rjkfgarBuMY79c0NwNoJPrU2Cw4kFhzz35/lU8RZRjGKp5O7IJJqzEQScn05pNDlsWYi2758gD0p7E46Y7DtTI8Yx1GcZqYkYGceo96Rk3qQOSdpyAO+eeeKSR2PORg96cw67gNpHpVZkUNgkjPvTVhpEiyE9TyScVNGVJ5J45PtVLzlyBkKAOfapwyZyHyuOmabQNWLUZyCoJyTwcUh/2Tz3zzTIyODu/SiT5uTgZ6VFg6iCVwDlR14wO1TW9wWzvDA/SqizRq2wuMjpmrScEDk56ZNKSLLkUoCfMSfpxTTslyu4bSMH6VEX2L+PNPXYwVl78nFZ2FtqcjJ4VSG4eQv5toyh0jfIKn1NMOQgV8ZXjiuwKiT7xwCOKy9R0nfIpt5ACW5B7jvW6quT99nbDEuWkjn45Psz+cuQc4yK6i0uWmhVwAeOaof2OwIEmDk9BWtbwrGm1etRUlGWqFWnGSGbBLIjyKrFCWQsMlSRjI9DgkfialurdGhwQGyMjuKstEi24lDfgaoC8jLBWbj0PWs9Wcyb3Rk6jottN8ypscflXN3MN7psn7oboyeB2rtZp0dhn8Kz7hRK+wr271vTqSjo9UdlLESWktjjdS1ES2s0fNvcOOHA6UthqMcNvDHM7SyAYZiK2rzQoXkDBu3esa606a2DeWgdDXbCdKceVHfGdOasiwdUb+HYR0rN1FkvoWguipjJ+7VDUrpbBAuCWJGFPWpLedZLcSXgO/ttHH/666I0eRKcTRUorYJLJUiTZgIg7HpVJLcXTMUVmX+92q+5Uxbo43bJ9apJJPbJJHDwpGVBPc1vBytvqapDv7MwCo796r2VsftK+SwmiyQ5HY+lMljn+zQCaaVHHU9R1qY30MMf7lgjd+OprT37WTuaRTGa1cGziDRj5s4AxXPz38jBTMScnp6VLrskt0Y25b1IrHMkzHYUJz0Jruw9BKCb3OHF4qVKbgr2NOwvEj1EKxOCcYxXVNdRQwGYjKr1xXG2FqQ/nTHDdhWzYyyQx7Ww2T0rPE04yd0dGDlUlTftFvqjo7e5S4gSWPJU9ARg1HZ3VzNLL58PlID8pPU1HEzEqFAVByRiltLr7RcSxRqSqj5ZOxrz3Gydl/wDSasaG4FlCmtG3gbKkNx6CqlpCWTcqke561s2ylY1LdT69q4qs7aI46srEib1Tsc9wOtRSSEsQBgjrmpt25cknJ7Cqks5T+Ede1c0VdnEX4GBUDPTB/yKtoSe+KoRH5sY4qQ3CIQGYqSMANxVM5eW+xpIRtPOBQVK4YE+wqujh48MBVgEYGB9etSZ2sMLHIOfwp5cNtB6nsOxqtcqeMHgdqkU74lcZUgYPaky7dSQ8HIHNWISAAGOTx+FUYjvAJ6Z44xU5dUUHjOPTrSYpLoXFcrGcketQi8TzFVmUZ6c9KybvVFjYgnB71yN94haDVxEY2KtyHxwK0p4edXSKNKdJS3O18SXt7BbxtpirNIzgMPQVU0vULy9hlF7biFw21ec5FYEerK5G584rX0K/Se6EbYJPqKqVJwhZx+Z0OiowOitrYRoCSN2KnBGMYGe1Zthr1lfy3CQs5MDBWLDGf8AOKsu/mAsmc1i007SOFxb1ZMrMO2RnmpNysPm/wD1VnNcyIB5i8EY3CnrP5sYCkZAx0pWHyMmleIHbjcc9cdaWOdwQo5PrVWOEr8+CAantoyHzxz04oaRpZJF1JeWODntVpHBRSBx7UyCMDBJyOtWpQFGVHPtWTMZNCBFYDBxT1XPJ6rVVpgrsDx6D1qubwhyCT34IosJRbNh7fKq25Tu7+tRahE1ljdtIPtXO6t4j/s+80+z8qSV7rJQoB8oHUmrV3qcl0Nsj7lXoSKTg0k2tGaRpybG3dw8pwjFcEZBqs8QcFu4HrVe51CFABJIqk9OaWGQygMduMYB9RVJaHR7OUVdksaNgkuB7nmnyIVXhuSfSiMgjjtUczkDKn8D2pmbu2VNSeSK2kaBTJKBlUz96sXT/tiFp7olTIP9Sf4a05rkQjLt361gatrAiYqpBbtx0+tdNGEpe7FbnZQhJqxk6zZLNdtPOWByOBUbK8Vu0uGlVBkIO9Uru7muMl+/OSKaLyQWvlhvxAr2I058qTPVgrIv2t1KLd5LpCu/hFHHHP8An8KrvMXcW+w+XIv+sU5xVZruWRUjkw0ajoetU5pXL4gkWMA9+4q40dWyuXlVy5I10IXhT5WiPy7jkuKzRK0wHnw7GHB4xVh5fMMU85xMnGAetZ+o3ZkHmZKqD0rppQd7WJqTVOPM38v62ILyUmcxoxVV9KrM7xzKd4aoZ5GNyzIMxuOGoby44j5jZPqK7owskeDVxDnKTvszQe6hhA8xwCe2atWKNeHhjsJ4wa51YY2Ys4LH610/hKJvPbglDyM9qxrxVODktzqwWKqYiqozXu+X6mxZSumyKRSkeSC0hwa17S1jTiJFCtz8vQ+9R3FlDdhBcoTsztxxWjYQJBEioMKoxzXh1aqautz0asi9ZptVWIIHpVokKe471XEoSPjnHtQJdy88fWvPabdzgndvUsBwBhR0GMDpiomClvmwD9BUTSndx0qR2XYC2MdMmi1jBqwz+0Yxqq2GyfzvL8wv5fyAduelM1fR01FYnEjx3EQ+Qg8Z96uibcMEHj17VKnHvj9avmcWpR0ZzxbiLpsMkFskcsm91ABarjFiQD064qKNgTjGPak3lsgDBHes3rqS7ydywGLKVz2quY2C7WchRzj1pv2hI8hnAx71Xe+iIw77hU2fQuMJF5XTbgk7ex9qrXd3GVOJAR6elZ0lyEARCpX1zzVG72hcowwferjSu9TohQvuZ2rXUbMzEknpxXNzzzSS8KcDpn0reNqssoVjhSeaeNPV2JiVQM9T6V6tKpCkrG/1fsYNrKwYZGAetdDpUohnR0JJFH9mp8q7Rnu1KlgUbKsScdKVWrCorD9k0rHSwwW5iJgVY/MbcwToT71rW8apCo3EA+prk7a4uY5gFH7nbnOec1uWupZUb48HHPevMqQkvM5p0pJaG0tuTFyfao4oNr5X8cUW93HINw4+p61J9qUABtu081hqcrUloSztIsWY0BGc1SF8gkCyZXsaln1CNY8RgMe2DVGC1NwTLPzzjFJW6mkael5GrBqMQU/vAAB+FOGo5H7oBlPcis6W1iVflUH6VVurtLTarkjJ4oUFJ6DjTi9jSlvWz85A+lUproE5JrG1/wC0vaItmWDlwTtOCBVL+0LaffCs482Lhxmt4UOZcyN4Ukbp1EqQSAQOhx0rA8TazJbWZaNsMxwKLuSfyoTbFSmfnz1xXK67qAnleIgMo7ehrrwuFUpp2O6lRSTkU31Oe5Ia5kJx0r0Hw3dt/Z0YdvMHY+1eY4RioKlQPQ123huWNbNEjYsAcc9q7cfSi6asiuVzi09TsRebMe9LLOFTBYe1V/KSWJckY69aDEi/M3IUcZ7V4VkcDgrmJqBuJXyFOPUDpzWO8Cidhc70HZsdTXX6ZeW9/vNtIH2NtbjpVqa0ilAWRFYDsRXVHEOk+Vqxqq/J7tjgNVjjihjS3kLsx6egrKEcguAHK+WeuDXcanocEmGhARs84HWufvbC4tnIZCVfjeF6V6GHxEZRsnqdlOrGfUyVt52ZhKMIT8pHeqs9jI8jYB2Dmr1yj28uxHLA9KdFb3IGSHIPUda61Ua1ubuMZK0jFYEBwobA7VGlm0ykv39a6SPS2eYMRtHpVqHRzuJY4HYYpvFxjszN0ITfv7HMw2whjChdy+lQ3djDMu0LtNdXdaYoDAOqfWqo0qLILStIcdhxRHFL4rlToU5Q9nZNGDpWjiV1LMxIP6V2VlZpbRAJgY702xsVgAaLJ+varyRSyNgKQM5ziuTE4l1XvoKlCnh4csFYfbqvu3rVK/1gR3Agt1DyKcSKcjA9aknkMSSMMHyxyMj8qx1kS5kme62xiVeFIwy4rGlTUnzS1QuW5vafqC3rTIilSjdT3pdVN21oRp5Bl9+1YsUEjIl5pkjuVAQIf1q3a6fdLch3uXUuwcr/ADolThGXMnt0ZjOMUa9ss7WsYlIM+0b8VMgJXAZlI/ugE/qDTPO8uTHbHOalV42GVIweRzwfxrkk3vY45oeJosZLAjqCKfHcqTtQsTXMm4kgmBkXHrkVsR3UYhDGRQT0xVzpOJDo2Whqs+1GkdtoUZOe1VbPUYr5HW2uIpcddrDioIZzOHjkBKsMHPFVoLKz06Z3gL75MZLuWJ/OoUFZp79DPkkpIsSxy4chVLn1NVRdLCxWWIbx6VY+1J9oZN6l8Z25qOdYbwtHwrIM7gOauPaS0OqGm5m3F0zzmReFx0WnRy/aWCKm0+p7VXuYngZluAQP4GXv9ajtIT5m5DtPrmuvljy3R2JRtoTXBeJx53zt61JDPuAEZG/IwKSaJjgklgKdY2omlC7WGfSpbjy3Y+ZJalpWccSMF59O9TphyRjaWHWtO00ZLdldm3r6HnFbP2aB02lAPwrinWV/dOKpiYrY5tLWcYMalsjt3q/Z2bBcy4BPatu3VFBVMYAxSuivkydfbvWTqNnJLEN6EH2ZFg2sefUDtVHU1iht3kLYVASST0rRIBQ4OAKyrxCzNHIMowwQaUdyabu7s40alPKuJbpEjaTCmIdPY1sWWpT2umXTJKyXLP8AKs54/DNaNtZ20IKi3jKlt2CvetuS3s5UUXUMbAcLuGeSegroq1oPRR0OudeKVmivpjzT6bBLOys7LklemaSaISN84VsHIyKutFCsAiiG1MbQB/DxWVpummwjkQyyTMxLZauVWd3sc6kndjL5W2kjkgVx9hJCZ7yea0Nu275mYfert5kY8AHB9qyLy1Eu6OVcq3XiuqjUUU0+ptTlYwNX1FoLVjAfkYfKRXEzSMxWQck9a7nxDZJBaRAJhBxx2rjbmzaFiwB2E8V7OBcOW6OqqpSgnHYgWTsW5rc0idoJIwjHaeaxxFt2mROvf1rpNKg8yA+VGqYxh36H2rbEyio6mmGTV+Y6/S7zzkOTyOKi1sCaW2tzeGCVzwCPvUulQvHGBLsB6/L3/wA8Vpy28dxLC0kSs6cgkZ2187KUYVLownJRndFi1gttLtTtRELcsVHU+tZOra8lknmMj7WO0YHJpLLTb5NQma7ufNgY5RQK0ZoEJUPGCoORkZrNKEZ3k+Yx91O71INNnF3ZpKARkZww5qZtrJh1BHoadvjRRudUVuAen5VLJGjRsHQFGBBUjIIqG1e5LdndGBe6OZLtfKRFhcYfj5h9DRFo5s7SRbVt8vXa561uMAANowB04qrcTJDlnOM9BWyr1GlE6I1Zy0M2c+W6IIDvZf1oayvZVz5ohHsMmpi0l4ykIBg5ye9aSuSny4GOCaqVRxtbc0lUcTGg0xyw+1FWJ6sO9XUtYYiAoGO9XUGIz8zN6+1ROgJ3HvxWbqyk9WR7RsZDbRbifLAGOtSMoJC4GPakLbR7Uxpdv3cYPrU6sm7bMx9BtWmuGbeBK4b73Q1PNplnM6M0AZ412hj6VcEgIGTz9aeCpGcZ/pWjq1OrG5yRzXk6nGWjs4IooRJ8uB2rfjiwAXAL8Z+tTgncO30oxk5PHoPWnOq59DOdRyM+6gydwHNZzSPDJtWMEnLEKM4+tbcpU5C7S+fuk81WljUjIABJ6nvVwnbcjn0sc7cTySk8DBqvFnAQg7icfSrAiLM2z5Tnp6UmXSZRIhwvI7V6CaSsjoUtNDYtVSJVX5gemDUs9mshLyMSR0H9aqQagAw82Mk+oq4bqSSRSAFX1PJrjkpp3MWpXuV0jtxdFjGvmAfePXFW7eeAofJgJPfjGalSxMhD8Hd3NaFrbLCMKgGe9ZTmmRKrFIyn0+W7cEkBcdD0q7b6SkcZyVBP91a0VXHH5ipAuMAd6ydST0MpYiWyM5LCEsFVcgfrVyGyijYMiBT7DrVmIKhyF6dxUwYEZPH1qW2zKVaTG7QQOQKYYt3c8+nUU/ACfITx3p0YZc469fSkZ8w+GE56k05owMg5pVfoGyMd6kB3R5x+HpRchtmdLkvwx+lRyqWHAz7VPMvBwQT3pqlTwoHPemaKViosXIIxj2q3C7BP3g78ZHSmztsO3nPtTAxRgcDpjGaT1NG+ZF5ACnFNBTcVJJOKapDITG3/ANaq7ko25lyPapsStSSWMYIXpVOWJSW7/WpRI3IJJ75NNBz6VWppFtGXfwxyWzRzoSh6j0965FPD85u2BObctkZ7ivQXto3BZhk9MVELYNIAyAhT8uRnFb0cTKkmonTTxHKrHL3Ph6OXy2IACDBAWlh0hfsD2jSPjduyODXW/Y4j8pjQ+2OBThaxgcYHPGKPrc7WuU8W2Ztlb7IwiggLhQT9Kv28ZDgt6VMEwDwOKV+MlRlgOAD1Nc8pNs55VOYQjLcGo1IYEn6c0PIc/Xj2qNZNqDd3/SosCRBf2MF3JC04bMZ3KAeDUjSncM4wO1RT3UZDKc59qrSs842rhFPUnrWii2knsaxi3uOvL3a4EfzE+lVYojNIWnJ+h7UuyONhtBLetS2zZiJY5BPetUlFe6br3VoTLH5Y2jkVMuBkD8qh3YXO7B6ZpEc5x261m02ZttlkhQepzUErgHHapNwJHcYqB/mc59OtKKBEckoQ49T3pm4E8frSSKm/kE49aYvXv1/OtkkaCkkY5/KrAdQo5/CqkpJPykAisn7TcC5kjkLBVOQe1aRpc41HmOnDJknP0pkkyjGO4rHS92Y3dCMk1Os6S4IORUexa3MZQaLMjjBKng/pVd3Yc5yffp+n0604nPA4PeqtwHZlwV2c53DPPGOc/X86uEUYt2GXkW2XehAzyRXOa5f3Ml0LS2BWY42nGAfauvdUuJQMnp61FFYBpsOBkd8ZropVY03eSvYcJ2ja9jPsI3MCLOR5oHOOla0Nq7BQQQp/CrMFosbhsA+1X0dVxxyD+Vc9Sq5PQU699h1tCsKAAn3ye9WVcYHY1GTlcKePX1qSM4XkE/hXO/M5m76ilTnPFSqpLc9qhMvzcA57Cnq+RnJH1NIh3Jt3AHQUuARkgVDC7PGrspUsASp6rkZ596kJ7DHNKwrD0XBI49OvNOAPXIx+tRBsd+alPOAp69qBC7iOT696RpAqc4+bgDNLjjrx0pjouQVxkcjigERkHO4gcUpjGM8ZpxJUANz+HWmuzYbaAADgc0yiIYLlAyFgM4yM49am2Jt5XJ6gZ61z9vcas2sNFdWS/ZMnbL3HpXQqx9PpROLjuaTVhyxqEwowD19zTXK5yQPXFKzEH1HTikZN5wQRgdaghEUqrIAccH0pvkqMY4FT7TsCggDrSBQDyeKZSZXMLK25HYj0PSmF2RhnkDrV0KrL3BqvNwPu7qEO4LKrKpGTxnilY57Yx0GOKhEYyGRsf7PanPKyg7o2IHpzRbsNLsJ5p24xnHv0qNpMHk5JprzIoJDA/wAzVGWeVmYLA+3HDZoUWzWMSzJJgZJOAaqXLM5DbSAD3p8e99oZCOckE8065z3Bx6VaVmarRlISDPQAH0FSK5OCB71XcHd9aVW5xnmtXE2RIxII7H1qVH2gLwf8ars29kXPTk1OzDA2ik0NjzgrzSKQGC7vzoHNQPE5mUgnaPepSQkicsA3ykfWl3gjGKhMUu/OQEH51E74XarYNNRuSyUjLMx5xVN5DuI7fSrIcFdpP/16YACQMVcdNy4shdiqbicDrVApJOqtLGVHBxnp7VsMAoOc881CfK67lBx3rSE7dBqRg3cFxbL8p8yE/mtWLaUKi847VNqdwghKggs3TFZ8IUNlmyD1A9a6o3nH3jVptGwsx25zz7VXuJU3Al1TOcYbGfWq63KiNs8Y75qm1wyr+9yVbkNn/JpQpanHUh2OrgVScqCpNWFIVznGTVS2JSIKDk1M2euOlcrRxFzII59aSLBQKG4HBx61XVhjAY5PPFTblLDPXoTmosJosxdCR0zjmpw+5fkbnj6VXRgFAyAMcU5CFPHUVm0BMxyc9D09afGp3VX8zLerVMrkADPbGaTQmSEkEdvc05COAKhZuwYYoDelFhExU9jinMW6KVDY+XPT2qv5zbjn6U5W3D5yOxxn05osOzJ4mk3HzMDHbPNPLYwB1x0qvnC4TG0dOcU4OO2CffvSaFYk3sRycg80gPXBJzUW3fk5IOOgNIPlb/HtRZDsSeZhQCR9KQEjcA3UkjPaoy+5hjBByc85qZCoHTr6Clawx43BwFYkdG3HoP5n8T3qUZLHpnpVYnGRj8aajnGTnmlYXKWh0yB+XFNbpgA/WkWQHOOD0pjhsHjj60WCw6OQjdjgVTun28hs+1SlztAI+tRzqMD+lCLSGQygABupqyjKeM5HeqKJhyec9OasHjJzxQ0OwlxbxyMTtH9aqKvlDaCSOuTVrd3qrdKpUhhxn1oXY0i3sG4A59O9RSy56UyQq0eM+3WoHbPBOQKtRNYojlKhcnBqLzVAJzjFNnm4AOMAVRhlaecADESnJ966Ywurs6Yx0NeBSRubALdBUwGVPcAZx61DGcgdMCnoxCkgjPUViyWypou+ZZnZ5SC+Ar8YrZCL37GmRMFAzn1pJHB6cA+9ROXPK5lKTbHzlVjJzjvxWFcyZJCA+ua0pJN3yLzxWbPG5fcpwK1oq24ohBnAz1qR5QjLyB3pigRAYPzHoKglRgQZGLNkk+wrWybOiGu5ZuGlmULDgL0JqBdNG0mVm/OtSFUEKs3XGc02N0kkJc8elQqjWkSXN9DnLjS5JGJhk4Xj5qV7Tyows2c+q1tsP3hCEbetNYIQS3BJyfet1Xl1Hzs5i4fyUfJAXPAxjFYU2pLIdrMwUHgqSM1c8T3DSXDxZxGDxjrXLT9QCAffNezhaKlHmkc2LreyVkj2OFtigdSe+c81ajOcc/nWZHJhTkc+vvU6yN0zhcY/n/8AWrw3E5bF9GHXjjjp/n1pQ4zk85qp5gyd35+9IJG3e3oO9RYfKy/G+TgtwPWnqxIyKpK3I5A+ven+YF9SBzjNQ0HKWUclgRhs+lTxSBwCvKnkH1qgrhmBJOM/XP41YWTA+X1ycnFJoTRcMmVOOPY0zd1A4/GqoZRgDIHWkaYDO1hkEKT7/wCSKOUSQjTuJPUegqeKYkA9M0wPuXBxz3I71GjIrHJ2tRa5e5dEoyASM9s9acGwc7u3TFVlIGSM+mf6CnK4QEZ5x6ZqbCsWo5AF3HgdTmnqQ6tht3vmqivvHIGP9oZ5+lSCbAb0HPAz2zQ0KxKhAPfPT60/ICdye1V2Ylsj8eMf578U0EO2P4jx9KmwWLauV5ZuD+NLvCg9N2egqqJs8fNxx06U4jA3g5bp71Nh2LKsCwJGD6U+fBj4PvVRJAWOCcZ+mf8AOKkdgVJGMjnmnYGiN5juwOaUHv6VWnJ6odpx/EOlMRyDwTnHbkCixVi0zbl4yKjkYkDFRGRiCvVu/vUby4BHHTkYo5SkidjkDnpVWckMQuMelPlcBc9T7VRkcIu1RgDoAOlVGNy4oZLKckZ/Wqc11gcGoriVt/t1qhNJtQs3AIziuynSudcIk13dlYSF+arGmDbbAtjcTnFc1FNLczui52E8n0roYW8uMFmOAPoMCuirS5I8pq3daGgJlQc8duKmjkVmBzkdcCsfzwXwzcHge1TLKiAYOBXNKkQ4G0kgJ5NLKcgEk/TNZq3UZGA3WpDMOepNYum0zJwLCAEk7hioLifap2AZHemQmV8nAC+3Gat29nvOZvu+9Oyi9SbqLuytplq9w/nvkr0GOK0LiBeh4I6VciAiARMDbjgdqSWJnyTj6VnKblK5i6zcjO24Tk8DsKgCqXbsCaNV862tZpII90noB1rPZbuazieNhFKQCykdK1hC6vc2i7rcuMUgRmduPc1iz61bmbYCPrVzUFkksZkHLbe3rXmzTH7S6NkMODXoYPCxrJtvYqVWFFJy6nQa+GuED2wVj3Irl7lXwCS0ZP1qU31xbvtB3Dt6VfilgueSiqepxxn/ADmvXpxlRjbdHHVnTxbai7Psz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells and gram-negative diplococci. Neisseria meningitidis, which is oxidase-positive, grew from this patient's sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_33_33311=[""].join("\n");
var outline_f32_33_33311=null;
